

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Joshua D. Hansen, Matthew Correa, Mark Nagy, Matt Alexander, Veronique Plantevin, Virginia Grant, Brandon Whitefield, Dehua Huang, Timothy Kercher, Roy Harris, Rama Krishna Narla, Jim Leisten, Yang Tang, Mehran Moghaddam, Katalin Ebinger, Joseph Piccotti, Courtney G. Havens, Brian E. Cathers, James Carmichael, Thomas O Daniel, Rupert Vessey, Lawrence G. Hamann, Katerina Leftheris, Derek Mendy, Frans Baculi, Laurie LeBrun, Gody Khambatta, and Antonia Lopez-Girona

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.9b01928 • Publication Date (Web): 04 Mar 2020

Downloaded from pubs.acs.org on March 5, 2020

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

*Joshua D. Hansen, * Matthew Correa, Mark A. Nagy, Matt Alexander, Veronique Plantevin, Virginia Grant, Brandon Whitefield, Dehua Huang, Timothy Kercher, Roy Harris, Rama Krishna Narla, Jim Leisten, Yang Tang, Mehran Moghaddam, Katalin Ebinger, Joseph Piccotti, Courtney G. Havens, Brian Cathers, James Carmichael, Thomas Daniel, Rupert Vessey, Lawrence G. Hamann, Katerina Leftheris, Derek Mendy, Frans Baculi, Laurie A. LeBrun, Gody Khambatta, Antonia Lopez-Girona*

Celgene Corporation, 10300 Campus Point Drive, Suite 100, San Diego, California 92121, USA.

1
2
3
4 KEYWORDS Ikaros, IKZF1, Aiolos, IKZF3, protein degradation, molecular glue,
5
6
7 immunomodulatory, CELMoD, lenalidomide-resistant, relapsed refractory multiple
8
9
10 myeloma.
11
12
13


14 **ABSTRACT:** Many patients with multiple myeloma (MM) initially respond to treatment with
15
16
17 modern combination regimens including immunomodulatory agents (lenalidomide and
18
19
20 pomalidomide) and proteasome inhibitors. However, some patients lack an initial
21
22
23 response to therapy (*i.e.*, are refractory) and, although the mean survival of MM patients
24
25
26 has more than doubled in recent years, most patients will eventually relapse. To address
27
28
29 this need, we explored the potential of novel Cereblon E3 Ligase Modulators (CELMoDs)
30
31
32 for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We
33
34
35 found that optimization beyond potency of degradation, including degradation efficiency
36
37
38 and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both
39
40
41 phenotypic and protein degradation data, we describe a series of CELMoDs for the
42
43
44 treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader
45
46
47 and the first CELMoD to enter clinical development that was specifically designed for
48
49
50 efficient and rapid protein degradation kinetics.
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Multiple myeloma (MM) is the second most common hematological malignancy in the US but constitutes less than 1% of all cancer types (~32,000 expected new diagnosed cases in 2020).¹ It is considered an orphan disease by the US Food and Drug Administration. Lenalidomide (**1**, Figure 1) has demonstrated significant improvement of overall survival rates (more than double compared to placebo + dexamethasone) and is approved in combination with dexamethasone for the treatment of MM. The widespread use of immunomodulatory drugs and proteasome inhibitors has come to represent the backbone of current standard-of-care therapy for MM patients. Despite these advances in the overall survival rate, there remains significant unmet medical need in both refractory and relapsed patient populations.²

Induction of protein degradation as a therapeutic strategy has been clinically validated by the class of immunomodulatory drugs, which include lenalidomide and pomalidomide (Figure 1). The therapeutic benefits of immunomodulatory drug treatment are connected to their ability to promote recruitment and ubiquitination of substrate proteins by the cullin-damaged DNA-binding-RING box-domain protein (CUL4-DDB1-RBX1-CRBN), or simply

1
2
3
4 (CRL4^{CRBN}) E3 ubiquitin ligase, with the resulting ubiquitin-tagged proteins directed to
5
6
7 and subsequently degraded by the 26S proteasome (Figure 2).^{3,4,5} In this manner,
8
9
10 lenalidomide directs cereblon (CRBN) to degrade Ikaros (IKZF1) and Aiolos (IKZF3),
11
12
13
14 initiating the downstream effects^{6,7,8} which were shown to be associated with the
15
16
17 antitumor and immunomodulatory properties of lenalidomide.^{9,10}
18
19
20
21
22
23



32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Structures of lenalidomide, pomalidomide, and CC-885.

Figure 2 a)




Figure 2 b)




Figure 2. a) Overview of the ubiquitin proteasome system. 1) The E1 enzyme catalyzes the activation of ubiquitin, leading to ubiquitin transfer to E2 conjugating enzyme. 2) Target substrate ubiquitination occurs after E2 transfers ubiquitin via the E3 ligase complex, to which the target is bound. 3) After ubiquitination,

1
2
3 the substrate is recognized by the proteasome for degradation. b) Magnified view of the E3 Ligase complex
4
5
6 model. Lenalidomide acts as a “molecular glue” to induce the binding of S (substrate; Ikaros/Aiolos) to
7
8
9 CRBN and drive the ubiquitination and ultimate degradation by the proteasome. Figure modified from ACS
10
11
12 Med. Chem. Lett. **2019**, *10*, 1592-1602.
13
14
15

16 Focused on a patient-oriented outcome, our goal was to develop a deeper knowledge
17
18
19 surrounding the degradation of Ikaros and Aiolos, the aspects of which we believed could
20
21
22 provide insight into the development of new protein degraders with enhanced efficacy in
23
24
25 MM and particularly in lenalidomide-refractory settings. The establishment and
26
27
28 characterization of a lenalidomide-resistant MM cell line, H929 R10-1 has been previously
29
30
31 reported, which in brief, results from the continuous treatment of H929 cells with
32
33
34 increasing doses of lenalidomide. In order to widen the possibility of finding novel
35
36
37 chemical matter as a starting point for investigation, we employed a phenotypic screen of
38
39
40 our CRBN modulator library using the lenalidomide-resistant H929 cell line. In conjunction
41
42
43
44 to the phenotypic approach, we screened for protein degradation, and since degradation
45
46
47 of Aiolos and Ikaros showed high correlation in previous test sets, and parallel results
48
49
50
51 would be expected, Aiolos was used as the representative target.
52
53
54
55
56
57
58
59
60

1
2
3
4 Recently, we described the structure-activity relationships of a series of urea-containing
5
6
7 compounds represented by **3** (CC-885, Figure 1) which were observed to degrade the
8
9
10 key proteins Ikaros and Aiolos, but also effected degradation of GSPT1 (eRF3a) with
11
12
13 variable levels of selectivity.¹¹ Urea **3** was included in the phenotypic screen and
14
15
16 displayed potent activity against H929 R10-1. Compound **3** however, was not suitable
17
18
19 for further development due to concerns about its toxicity profile. Compound **3** was not
20
21
22 tolerated after a single dose in cynomolgus monkeys (data not shown), which we
23
24
25 correlated to the lack of an *in vitro* selectivity ratio between the viability of normal
26
27
28 peripheral blood mononuclear cells (PBMCs) from healthy donors versus the target
29
30
31 lenalidomide-resistant cells (Figure 3). We removed from consideration compounds like
32
33
34 **3** that had little to no *in vitro* selectivity and focused on the leads with high cell viability in
35
36
37 PBMCs ($IC_{50} > 5 \mu M$). As expected, lenalidomide demonstrated no activity against H929
38
39
40 R10-1, and pomalidomide showed poor activity clustering, with a group of analogs in a
41
42
43 half-micromolar potency range. On the other extreme, we identified compound **13** which
44
45
46 showed little effect on PBMC viability yet displayed potent single digit-nanomolar
47
48
49 antiproliferative activity against the lenalidomide-resistant cell line (Figure 3).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Using **13** as a lead structure, we resolved to explore the SAR of this series (Figure 4)
4
5
6
7 as it related to both lenalidomide-resistance activity as well as preservation of selectivity
8
9
10 against PBMCs. Herein, we describe the design and synthesis of a series of potent aryl
11
12
13
14 piperazine-containing compounds that exhibit deep levels of protein degradation with
15
16
17 rapid degradation kinetics, leading to preclinical activity for the treatment of RRMM. The
18
19
20
21 optimization of degradation efficiency in this series which translated to strong induction of
22
23
24 apoptosis, culminated in the identification of **4** (CC-92480), the first CELMoD entering
25
26
27
28 clinical development that was specifically designed for high efficiency and rapid kinetics
29
30
31 of protein degradation.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Phenotypic screen of CELMoDs in which in vitro sensitivity toward PBMC viability is plotted against lenalidomide-resistant MM cell viability (H929 R10-1). Compounds above the diagonal line have stronger activity in H929-1051 cells than in PBMC. Lenalidomide (Len), pomalidomide (Pom), and CC-885 are colored in yellow.




Figure 4. Structures showing the scope of SAR described, leading to **4** (CC-92480).

CHEMISTRY

The chemistry efforts toward CC-92480 (**4**) involved the preparation of several analogs accessed through varying synthetic routes, which are outlined in the following schemes and Supporting Information. Synthesis of key amine **8** (Scheme 1) began with regioselective methyl esterification of the gamma carboxylic acid group of glutamic acid (**5**), followed by boc protection of the amine to give **6**. Conversion of the alpha carboxylic acid to a primary amide followed by acidic boc deprotection gave amine **8**.

1
2
3 The synthesis of the key intermediates **12a-b** (Scheme 2) began with Fischer
4 esterification of 3-hydroxy-2-methylbenzoic acid (**9**), followed by radical bromination of
5
6 the tolyl-methyl group.¹² Formation of the isoindolinone **11** was accomplished via bromide
7
8 displacement using methyl 4,5-diamino-5-oxopentanoate (**8**) as the nucleophile, followed
9
10
11
12
13
14
15
16
17
18 by base-mediated cyclization. After silyl deprotection, the requisite benzyl spacer could
19
20
21 be installed either via phenol alkylation with 1,4-bis(bromomethyl)benzene or by
22
23 Mitsunobu reaction with (4-(chloromethyl)phenyl)methanol. In the case of benzyl bromide
24
25
26
27
28 intermediate **12a**, the glutarimide functionality was obtained through treatment of the
29
30
31 primary amide with potassium *tert*-butoxide at low temperature. Alkylation of the benzyl
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
benzyl chloride intermediate **12b**, alkylation of the chloride with the desired amine nucleophile
occurred first and was followed by closure of the glutarimide ring using the low
temperature, potassium *tert*-butoxide conditions mentioned above.

To evaluate the dependence of CRBN-binding, the N-methyl analog of **13** (**39**) was
accessed through alkylation of the glutarimide functionality as outlined in Scheme 3.
Benzyl intermediate **36** was synthesized by silyl protection of benzyl alcohol **35**, followed


1
2
3 by reduction of the ester and subsequent conversion of the resulting benzyl alcohol to
4
5
6
7 benzyl bromide **36**. Closure of the glutarimide ring with potassium *tert*-butoxide was
8
9
10 followed by silyl deprotection and alkylation of the glutarimide nitrogen with methyl iodide
11
12
13 to provide **38**. Conversion of the benzyl alcohol of **38** to the corresponding mesylate
14
15
16
17 allowed for alkylation with 1-(2,4-difluorophenyl)piperazine to give compound **39**.
18
19
20

21 SAR exploration of analogs containing the phthalimide core was supported by the
22
23
24 synthesis described in Scheme 4 which began with the reaction of phthalic anhydride **41**
25
26
27 and 3-aminoglutarimide to give compound **42**. Alkylation of phenol **42** with previously
28
29
30 described benzyl bromide **36** was followed by acidic silyl deprotection and conversion of
31
32
33 the resulting benzyl alcohol to mesylate **44**. This penultimate intermediate provided a
34
35
36
37 common access point to compounds **45-47**.
38
39
40

41
42 For purposes of linker SAR, the nitrogen-linked analog of lead compound **13** was
43
44
45 obtained in convergent fashion by reductive amination of lenalidomide (**1**) with
46
47
48 functionalized aldehyde **49** which was obtained in one step from commercial 4-
49
50
51 (bromomethyl)benzaldehyde (Scheme 5).
52
53
54
55
56
57
58
59
60

1
2
3 The synthesis of chiral alpha-methyl glutarimide analog **58** shown in Scheme 6 began
4
5
6
7 with formation of imine **52** from methyl L-alaninate (**51**) and benzaldehyde. Ensuing
8
9
10 addition of prop-2-enamide followed by acidic imine hydrolysis provided racemic 3-amino-
11
12
13
14 3-methylpiperidine-2,6-dione (**53**). Addition of menthol derivative **54** to the amine provided
15
16
17 the necessary chiral auxiliary to enrich for the desired S-enantiomer. Compound **56** was
18
19
20 obtained in high enantiomeric excess after crystallization of **55** followed by carbamate
21
22
23 hydrolysis. Formation of the isoindolinone core was achieved by bromide displacement
24
25
26
27 of **10** and subsequent trimethylaluminum-mediated condensation to give lactam **57**. A
28
29
30 one-pot base-mediated silyl deprotection and alkylation of the liberated phenol with
31
32
33
34
35 benzyl bromide **63** provided the target alpha-methyl glutarimide analog **58**.
36
37


38
39 Synthesis of amide-linked piperazine analogs shown in Scheme 7 was achieved
40
41
42 through a slight modification of the route described in Scheme 2. Alkylation of lactam **11**
43
44
45 with benzyl bromide ester **64**, followed by formation of the glutarimide ring with potassium
46
47
48 *tert*-butoxide and acidic hydrolysis of the *tert*-butyl ester provided the perfluorophenyl
49
50
51 acetate **67** which afforded a common intermediate from which compounds **68-71** were
52
53
54
55
56 accessed through amide formation with their respective N-aryl piperazines.
57
58
59
60



Reagents and conditions: (a) H_2SO_4 , MeOH, 65 °C, 17 h, 88%; (b) TBSCl, imidazole, 25 °C, 1 h, DCM, 75%; (c) AIBN, NBS, 65 °C, 2 h, EtOAc, 98%; (d) **8**, DIEA, 60 °C, 16 h, ACN, 76%; (e) K_2CO_3 , H_2O , RT, 15 h, DMF, then HCl, 77%; (f) 1,4-bis(bromomethyl)benzene, K_2CO_3 , 60 °C, 16 h, ACN, 63%; (g) (4-(chloromethyl)phenyl)methanol, PPh_3 , DIAD, 0 °C, 1.5 h, THF, 92%; (h) $t\text{-BuOK}$, -78 °C, 2 h, THF, 93%; (i) Substituted phenyl/alkyl piperazines/piperidines, DIEA, 40 °C, 18 h, ACN, 18%-90%; (j) Substituted


phenyl/alkyl piperazines/piperidines, DIEA, 40 °C, 18 h, ACN, 45%-60%; (k) *t*-BuOK, 0 °C, 5 min, THF, 36-50%.

Scheme 3. Synthesis of the *N*-methyl glutarimide compound 39.




Reagents and conditions: (a) TBSCl, imidazole, 0-25 °C, 16 h, DMF; (b) LiAlH₄, 0 °C, 1 h, THF, 80% over 2 steps; (c) NBS, Me₂S, -20-25 °C, 2 h, DCM; (d) **37**, K₂CO₃, 30 °C, 4 h, DMF, 44%; (e) *t*-BuOK, 0 °C, 1 h, THF; (f) H₂SO₄, 20 °C, 2 h, THF, 84% over 2 steps; (g) MeI, K₂CO₃, rt, 5 h, DMF, then HCl, 72%; (h) MsCl, DIEA, -5 °C, 1 h, DMF; (i) 1-(2,4-difluorophenyl)piperazine, DIEA, 30 °C, 16 h, DMF, 25% over 2 steps.

Scheme 4. Synthesis of analogs containing the phthalimide core.




Reagents and conditions: (a) 3-aminopiperidine-2,6-dione, AcONa, 100 °C, 2 h AcOH, 71%; (b) **36**, K₂CO₃, 20 °C, 3 h, DMF, 38% over 2 steps; (c) H₂SO₄, 24 °C, 30 min, THF, 85%; (d) MsCl, DIEA, 20 °C, 2 h, DMF (e) Substituted phenyl piperazines, DIEA, 24 °C, 16 h, DMF, 33-36%.

Scheme 5. Synthesis of the *N*-linked compound 50.




Reagents and conditions: (a) 1-(2,4-difluorophenyl)piperazine, TEA, RT, 16 h, ACN, 95%; (b) Lenalidomide (1), NaBH₄, 100 °C – 25 °C, 3 h, AcOH, 48% over 2 steps.

Scheme 6. Synthesis of the chiral-methyl glutarimide compound 58.



Reagents and conditions: (a) MgSO_4 , TEA, PhCHO, rt, 16 h, DCM; (b) prop-2-enamide, $t\text{-BuOK}$, NH_4Cl , 0 °C, 30 min, THF, 75% over 2 steps; (c) HCl, 10 °C, 3 h, THF, 96%; (d) **54**, NaHCO_3 , 0 °C, 2 h, THF, water, 9%; (e) HBr, AcOH, 90 °C, 6 h, 87%; (f) **10**, DIEA, rt, 16 h, ACN; (g) AlMe_3 , 110 °C, 2 h, toluene, 54% over 2 steps; (h) NaBH_4 , 0 °C, 2 h, MeOH, 87%; (i) SOBr_2 , rt, 2 h, DCM, 91%; (j) **63**, K_2CO_3 , rt, 16 h, DMF, 73%.

Scheme 7. Synthesis of amide-linked piperazine analogs.




26
27
28
29
30

Reagents and conditions: (a) **64**, K_2CO_3 , 25 °C, 4 h, NMP, 57%; (b) $tBuOK$, -70 °C, 90 min, THF, 73%; (c) TFA, 25 °C, 12 h, DCM, 100%; (d) Perfluorophenyl 2,2,2-trifluoroacetate, DIEA, THF/DMF, 57%; (e) Substituted phenyl piperazines, DIEA, RT, 10 min, DMF, 50-74%.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Scheme 8. Asymmetric synthesis of 4.



Reagents and conditions: (a) tert-butyl (4S)-4,5-diamino-5-oxo-pentanoate, DIEA, 50 °C, 16 h, ACN; (b) TBAF, rt, 16 h, MeOH, 60% over 2 steps; (c) 1,4-bis(chloromethyl)benzene, DIEA, 60 °C, 1 h, ACN/DMF, 67%; (d) **73**, K₂CO₃, 45 °C, 16 h, DMF, 100%; (e) benzenesulfonic acid, 85 °C, 18 h, ACN, 72%, 98% e.e..

RESULTS AND DISCUSSION

1
2
3
4 Since the mode of action of targeted protein degraders (molecular glue and
5
6 heterobifunctional molecules/PROTACs) hinges upon removal of a disease-associated
7
8 protein through an event-driven process (formation of the ternary complex to facilitate
9
10 ubiquitin transfer) whereby the degrader can facilitate multiple rounds of degradation, the
11
12 ratio of the number of molecules of target proteins degraded per molecule of degrader
13
14 compound should be $\geq 1:1$. After the protein is tagged with ubiquitin and degraded, the
15
16 degrader molecule becomes available to engage in the formation of a ternary complex
17
18 with additional protein, thus degraders have the potential for catalytic-like efficiency. The
19
20 degradation efficiency is inherent to and reflected by the level of protein remaining over
21
22 a time course of measurement, generally 4 h in the case of work described in this
23
24 communication. The level of protein remaining is denoted by percent of control on the Y-
25
26 axis of the degradation curve, and the point at which the curve reaches a minimum (Y_{\min})
27
28 depicts the minimum percent protein remaining (Figure 5). Percent protein remaining
29
30 (Y_{\min}) is reached when degradation and protein synthesis reach an equilibrium, and thus
31
32 comparisons of Y_{\min} values would reveal which compounds can more effectively induce
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 protein degradation (lower Y_{\min}). It is worth pointing out that for targets with very fast
4
5
6
7 protein resynthesis, a low Y_{\min} requires fast degradation kinetics.
8
9

10 Comparison of degradation efficiency can be drawn across groups of compounds
11
12
13 assayed under the same conditions and timeframe. As a relevant example, lenalidomide
14
15
16 and pomalidomide display a differential in Aiolos degradation efficiency (Figure 5). After
17
18
19
20
21 4 hours lenalidomide demonstrates the least efficient degradation at $Y_{\min} = 35$ (35 %
22
23
24 protein remaining), and pomalidomide shows improved degradation efficiency with $Y_{\min} =$
25
26
27
28 18. This differentiated pharmacology is clinically correlated with a greater efficacy of
29
30
31 pomalidomide which can achieve responses in lenalidomide-refractory patients.¹³ The
32
33
34 novel degrader CC-92480 (**4**), in addition to a dramatic increase in potency shows
35
36
37
38 significant improvement in degradation efficiency as measured by the depth of protein
39
40
41 degradation ($Y_{\min} = 5$), a parameter we expect to translate into higher clinical efficacy in
42
43
44
45 RRMM patients.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 5. Aiolos degradation curves (4h) of pomalidomide (Pom), lenalidomide (Len), and CC-92840 (**4**). Y_{min} is the lowest point of the dose-response degradation curve and denotes the minimum % protein remaining.

The identified lead **13**, in addition to potent antiproliferative activity in the lenalidomide-resistant line (H929 R10-1), also displays potent and efficient degradation of Aiolos. (Figure 6). To assess the minimum pharmacophore, we explored the effect of a systematic truncation/simplification of the terminal aryl in lead **13**. To begin, the 2,4-difluoro substitution was removed yielding the phenyl analog **21**, which retained both excellent antiproliferative activity as well as Aiolos degradation potency and efficiency. Replacement of phenyl with *i*-propyl, as exemplified in analog **22**, led to a loss in desired antiproliferative activity. It is worth noting that the loss in antiproliferative activity (~20x compared to **13**) was not mirrored by the same loss (3x) of Aiolos degradation potency. However, the degradation efficiency of **22** is lower (13% remaining as compared to 6%


1
2
3
4 for **13**) and may help rationalize the large loss in antiproliferative potency. A further
5
6
7 reduction of size, in which the terminal aryl found in **13** was replaced with methyl (**34**), led
8
9
10 to a sharp activity drop (300x) in antiproliferative activity which correlates with
11
12
13 concomitant loss in Aiolos degradation potency and efficiency. Finally, removal of the
14
15
16 piperazine group in **40**, where the O-benzyl substituent becomes the terminus abolished
17
18
19 antiproliferative activity in the H929 R10-1 cell line.
20
21
22
23
24
25
26
27

**13**


H929 R10-1 IC₅₀ = 0.0017 μM
Aiolos EC₅₀ = 0.00010 μM
Aiolos Y_{min} = 6

**21**


H929 R10-1 IC₅₀ = 0.0021 μM
Aiolos EC₅₀ = 0.00010 μM
Aiolos Y_{min} = 5

**22**

H929 R10-1 IC₅₀ = 0.035 μM
Aiolos EC₅₀ = 0.0003 μM
Aiolos Y_{min} = 13

**34**

H929 R10-1 IC₅₀ = 0.51 μM
Aiolos EC₅₀ = 0.003 μM
Aiolos Y_{min} = 28


**40**










H929 R10-1 IC₅₀ = > 10 μM
Aiolos EC₅₀ = 0.0075 μM
Aiolos Y_{min} = 62

1
2
3 **Figure 6.** An SAR exploration in which systematic reduction in size from lead **13**, defines the minimum
4 pharmacophore to include an aryl substituted piperazine.
5
6

7 The requirement of the 2,4-difluoro substitution present in **13** was next examined,
8
9 represented by a selected set of data in Table 1. It is readily apparent that changing the
10
11 substitution pattern of aryl-fluoro groups (**13-17**) made little impact on either
12
13 antiproliferative activity, or degradation potency/efficiency. Compound **18**, the chloro
14
15 analog of **13** maintained potency showing only a minimal loss (5x) in antiproliferative
16
17 activity. Electron donating groups were also assessed as exemplified by **20** and
18
19 maintained comparable activity to **13**. Taken together, we found the substitution at the
20
21 terminal aryl to have little impact on antiproliferative activity or Aiolos degradation.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Analogues of **13** maintained a similar PBMC viability profile and additionally when measured
for degradation selectivity, piperazine **13** and its closely related analogs were devoid of
GSPT1 degradation activity.

Table 1. Effect of substitution at the terminal aryl group.^{a,b,c}




Compd	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	GSPT1 EC ₅₀ (nM)
13		1.7	0.1	6	>10,000
14		2.8	0.1	5	>10,000
15		3.7	0.1	6	>10,000
16		5.0	0.2	6	>10,000
17		4.0	0.3	7	>10,000
18		9.2	0.2	8	>10,000
19		3.6	0.1	6	>10,000
20		7.1	0.5	9	>10,000
21		2.1	0.1	5	>10,000

^aAll values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining followed by treatment with compound concentrations up to 10 μM, and measured after 4 h (see methods).

It was anticipated based on previously established SAR, and confirmed by crystallography,¹⁴ that the glutarimide moiety is an important binding partner to CRBN, and the glutarimide N-H makes a hydrogen-bond interaction with His378 contributing to

CRBN binding affinity. To this end, we synthesized the *N*-methyl glutarimide analog of **13** (**39**). As expected, methylation of the glutarimide disrupts CRBN binding and translated into a >370-fold loss of activity in both degradation and proliferation (Table 2).

Table 2. Effect of *N*-methyl cap at glutarimide. ^{a,b,c}




Compd	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	GSPT1 EC ₅₀ (nM)	CRBN Binding IC ₅₀ (nM)
13	H	1.7	0.1	6	>10,000	55.1
39	Methyl	632	>10,000	93	>10,000	28,000

^aAll values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining followed by treatment with compound concentrations up to 10 μM, and measured after 4 h (see methods).

The structural difference between lenalidomide and pomalidomide (Figure 1) is an additional carbonyl group in the scaffold of pomalidomide (oxoisoindoline versus dioxoisoindoline), the presence of which in pomalidomide favorably impacts the efficiency and potency of Aiolos degradation (Figure 5). However, in the context of lead **13**, we found that the dioxoisoindoline core led to the opposite activity profile (Table 3).


1
2
3
4 Comparison of **13** to **45** reveals that while GSPT1 selectivity was retained, there was a
5
6
7 24-fold loss in Aiolos degradation potency in combination with reduced degradation
8
9
10 efficiency by 17%. The loss in degradation efficiency apparently drove the nearly 100-fold
11
12
13 loss in H929 R10-1 antiproliferative potency. The trend was similar for related analogs **46**
14
15
16
17 and **47** in which introduction of the second carbonyl into the scaffold had a detrimental
18
19
20
21 effect on activity.
22
23
24
25
26
27

28 **Table 3.** Effect of dioxoisindoline scaffold in terms of antiproliferative activity in the lenalidomide-resistant
29 cell line H929 R10-1, CRBN binding, and the degradation of Aiolos and GSPT1. ^{a,b,c}
30



38
39
40
41
42
43
44
45
46
47
48
49
50
51
52


Compd	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	GSPT1 EC ₅₀ (nM)	CRBN Binding IC ₅₀ (nM)
45		159	2.4	23	>10,000	502
46		146	2.1	18	>10,000	322

47		170	3.3	30	>10,000	877
-----------	---	-----	-----	----	---------	-----

^aAll values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining following treatment with compound concentrations up to 10 μM, and measured after 4 h (see methods).

Again, in reference to the structural features of pomalidomide and lenalidomide (Figure 1), both drugs contain an NH₂ functional group at the 4-position of the isoindoline scaffold. To assess the effect exerted by either nitrogen or oxygen as a tether point to the isoindoline core, we synthesized **50** (Table 4) as a direct comparator to **13**. The difference between **13** and **50** asserts the view that the action of binding to CRBN does not directly translate to degradation potency, but rather, is just one of the necessary steps toward formation of the ternary complex requisite for ubiquitination of substrate. In this case, the CRBN binding IC₅₀ of the *N*-linked compound **50** was only 2-fold lower than that of **13**, yet the Aiolos degradation potency was reduced by 15-fold and level of protein remaining increased from 6% to 15%, ultimately leading to a 15-fold loss in antiproliferative potency.

Table 4. Effect of oxygen versus nitrogen-linked oxoisoindoline scaffolds. ^{a,b,c}




Compd	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	GSPT1 EC ₅₀ (nM)	GSPT1 Y _{min}	CRBN Binding IC ₅₀ (nM)
13	O	1.7	0.1	6	>10,000	93	502
50	N	26.3	1.5	15	>10,000	90	194

^aAll values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining following treatment with compound concentrations up to 10 μM, and measured after 4 h (see methods).

Pomalidomide, lenalidomide, and thalidomide (Figure 1), contain a chiral center at the tertiary glutarimide carbon and this chiral center is known to be unstable and can undergo racemization.^{15,16} In the case of thalidomide, crystallographic and binding data supports that the *S*-enantiomer has stronger binding to CRBN.¹⁷ To identify if a single enantiomer could be largely responsible for the activity, both enantiomers of **13** were independently evaluated (Table 5). In the proliferation assay, we found there was no appreciable difference in activity when comparison was drawn between the two enantiomers (**60** and **61**), or a single enantiomer and the racemate. Additionally, we found that while either enantiomer could degrade equivalent total levels of Aiolos (Y_{min}), the *S*-enantiomer **60** did

1
2
3 have a 5-fold lower Aiolos EC₅₀ value than *R*-enantiomer **61**. The largest difference
4
5
6
7 between enantiomers was observed in connection to CRBN binding, where the *S*-
8
9
10 enantiomer **60** was clearly more potent (~30-fold) compared to the *R*-enantiomer **61**.

11
12
13
14
15
16
17
18 **Table 5.** Activity table examining the effect of chirality on antiproliferative activity in the lenalidomide-
19 resistant cell line H929 R10-1, CRBN binding affinity, and degradation of Aiolos. ^{a,b,c}




29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Compd	*	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	CRBN Binding IC ₅₀ (nM)
13	1:1	H	1.7	0.1	6	502
61	(<i>R</i>)	H	4.3	0.5	7	1158
60	(<i>S</i>)	H	3.8	0.1	5	37
59	(<i>R</i>)	Me	> 5,000	> 100	94	9,618
58	(<i>S</i>)	Me	496	>10	93	>10,000

48
49
50
51
52
53
54
55
56
57
58
59
60

^aAll values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining following treatment with compound concentrations up to 10 μM, measured after 4 h (see methods).

1
2
3
4 One possible explanation for the apparent discrepancy between binding affinity and
5
6
7 antiproliferative activity of the two enantiomers could be found in the rate of racemization.
8
9
10 Figure 6 depicts a measurement of racemization when the *S*-enantiomer **60** was placed
11
12
13 in cell media and its concentration measured over time. Increasing concentration of *R*-
14
15
16 enantiomer **61** is observed over time corresponding to loss of the *S*-enantiomer, with
17
18
19 complete racemization within ~24 h. In the case of the cellular antiproliferation assay, the
20
21
22 assay time (120 h) exceeds the time to racemization (~24 h), thus precluding the
23
24
25
26
27
28 measurement of single enantiomer activity. On the other hand, the CRBN binding assay
29
30
31 (4 h) does not exceed the time to racemization and could potentially discriminate activity
32
33
34
35 between the enantiomers.
36
37
38
39



1
2
3 **Figure 6.** Chiral monitoring over 24 h where the disappearance of the S-enantiomer corresponds with the
4 appearance of the R-enantiomer. This study used the same cell media as the one used for the H929 R10-
5 1 antiproliferative assay.
6
7

8
9 Additional investigations were made to elucidate the effect of the chiral center on
10
11 activity. To this end, we placed a methyl group at the glutarimide chiral center (**58** and **59**,
12
13 Table 5) which would lock defined chirality and remove the potential of racemization over
14
15 time. Both enantiomers however, suffered a loss in activity both in terms of degradation
16
17 as well as CRBN binding, showing that substitution at the chiral center was not tolerated.
18
19
20
21
22
23
24
25

26 Having completed an overview of the main SAR about analog **13**, which included
27
28 exploration of a glutarimide substitution, the core scaffold, linker, and a minimum
29
30 pharmacophore definition at the piperazine terminus, it was important to identify potential
31
32 liabilities that might prevent further development of this series. Several preclinical assays
33
34 were used to evaluate **13**, starting with the *in vitro* safety profile.
35
36
37
38
39
40
41
42


43 Analog **13** was screened against a panel of 80 receptors to assess potential off-target
44
45 activity. At a concentration of 10 μM , compound **13** demonstrated inhibition equal to or
46
47 greater than 50% for 26 targets. The % inhibition of the α_1 adrenergic receptor was
48
49 101.5% and 99.1% for the dopamine D_{2S} receptor (Table 6). Upon further assessment in
50
51
52
53
54
55
56
57
58
59
60

1
2
3 follow-up functional assays, **13** displayed potent activity against multiple targets. For
4
5
6
7 example, the compound had a functional $IC_{50} = 14$ nM in the α_1 adrenergic receptor assay
8
9
10 and a strong agonist activity in the dopamine D_{2S} receptor assay with an $EC_{50} = 16$ nM
11
12
13 (Table 9). The observed in vitro dopamine D_{2S} activity was relevant in vivo.¹⁸ Rodents
14
15
16
17 dosed daily for 7 days with **13**, showed a gut motility suppression in alignment with the
18
19
20
21 observed in vitro activity (data not shown).
22
23

24 To address the off-target activity of **13** a more detailed SAR investigation was carried
25
26
27 out at near the piperazine terminus (Table 6). Since isopropyl substituted piperazine **22**
28
29
30 was a truncation that maintained activity in the Len-resistant model, we compared **22** to
31
32
33
34 piperidine analog **23**. Compound **23** demonstrated an increased (~25-fold)
35
36
37
38 antiproliferative potency as well as an increased depth of Aiolos degradation (Table 6).
39
40
41
42 Further reduction in terminal group size (**24-27**) decreased antiproliferative potency as
43
44
45 well as the depth of Aiolos degradation compared to **23**. Since **23** demonstrated an
46
47
48 excellent activity profile, further assessment of off-target binding revealed significant
49
50
51
52 improvement compared to **13**. Using reduction of molecular weight as a general strategy
53
54
55
56 for this series to reduce the number of off-target hits, compounds **24**, **25**, and **27**
57
58
59
60

mentioned above also showed a reduction in the number of off-target activities compared to **13**. However, compounds in this series were not further developed due poor ADME attributes including fast in-vivo clearance and poor bioavailability.

Table 6. Activity table of truncated compounds. ^{a,b,c,d}









Compd	X	R	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	α ₁	D _{2S}
13	CH		1.7	0.1	6	101.5	99.1
22	N	<i>i</i> Propyl	35.1	0.3	13	ND	ND
23	CH	<i>i</i> Propyl	1.4	0.1	7	63.0	94.0
24	CH	CF ₃	8.3	0.6	10	41.5	95.4
25	C	Me, Me	9.9	0.3	11	21.5	66.0
26	C	F, F	20.5	0.5	12	ND	ND
27	CH	Methyl	35.1	1.0	18	40.4	78.4

^aAntiproliferative and Aiolos degradation values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining same comments 10 μM, after treatment for 4 h (see methods). ^dα₁ & D_{2S} reported as % inhibition @ 10 μM, ND, not determined.

1
2
3
4 To test the hypothesis that the poor off-target receptor profile of **13** was in part due to a
5
6
7 combination of higher molecular weight and lipophilicity or the presence of an embedded
8
9
10 basic site, a series of non-basic analogs was explored. The direct non-basic comparator
11
12
13 to **13**, compound **68**, maintained equivalent antiproliferative activity, and Aiolos
14
15
16 degradation depth and potency (Table 7). This activity profile was shared by compounds
17
18
19 in the series (**69-71**), while removal of basicity in piperazinone analog **28** did result in a
20
21
22 loss of Aiolos degradation efficiency. The lowering of lipophilicity (cLogP = 3.6 (**13**) vs 2.8
23
24
25 (**68**)) in combination with removal of the most basic site which was associated with
26
27
28 reduction in the number of off-target receptor hits (26 vs 4, respectively). Where
29
30
31 lipophilicity was comparable (**71**), the effect of basic site removal was also significant
32
33
34 indicating that the piperazine could be in part responsible for the poor off-target receptor
35
36
37 binding profile. Unfortunately, further development of this series was hampered by poor
38
39
40 permeability and low solubility (<7 ug/mL).
41
42
43
44
45
46
47
48

49 **Table 7.** Effect of basic site removal at the piperazine. ^{a,b,c,d}




Compd	R ₁	R ₂	R ₃	H929 R10-1 IC ₅₀ (nM)	Aiolos EC ₅₀ (nM)	Aiolos Y _{min}	cLogP	α ₁	D _{2S}
68		O	H,H	4.9	0.1	7	2.8	70.3	0.4
69		O	H,H	3.7	0.3	8	2.8	ND	ND
70		O	H,H	6.2	0.1	7	3.1	33.7	7.9
71		O	H,H	3.3	0.1	7	3.5	74.1	5.6
28		H,H	O	6.7	0.6	11	3.9	ND	ND

^aAntiproliferative and Aiolos degradation values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining same comments 10 μM, after treatment for 4 h (see methods). ^dα₁ & D_{2S} reported as % inhibition @ 10 μM, ND, not determined.

Since it was advantageous from physiochemical property and ADME point of view to maintain the piperazine moiety, we explored the introduction of polarity via heterocycles at the terminal aryl (Table 8). The 4-fluoro pyridyl analog **29** is a direct comparator to **14**. While activity was maintained in both the antiproliferative and degradation assays, the addition of the pyridyl group (**29** or **30**) had little impact toward the improvement of the off-target profile as evident from the strong inhibition of α₁ and D_{2S}. Nevertheless,

1
2
3 encouraged by the activity profile of the pyridyl analog, we examined a series of
4
5
6 substituted pyridyl groups with varying polarity. The Aiolos degradation profile was
7
8
9 maintained with both the picolinamide as well as aryl nitrile, but there was an interesting
10
11
12
13
14 subtlety between the effect of these functional groups on the off-target binding profile.
15
16
17 While the picolinamide functionality in compound **31** imparted a reduction in α_1 and D_{2S}
18
19
20 binding potency, the ortho-aryl nitrile group in **32** effected minimal impact toward off-target
21
22
23 binding potency in α_1 and D_{2S} and this analog hit 25/80 receptors in the panel with a
24
25
26 potency greater than 50% at 10 μ M. Since the nitrile function in **32** did not reduce off-
27
28
29 target binding, we were surprised to find that moving the nitrile group to the 4-position
30
31
32 both maintained the desired activity profile as well as increased the selectivity against off-
33
34
35 target binding. Encouraged by this result, **33** was tested in follow-up assays and
36
37
38
39 determined to have low off-target functional activity compared to **13** (Table 9), and absent
40
41
42
43
44
45 of effects on gut motility in rat (data not shown).
46
47

48
49 **Table 8.** Effect of polarity and heterocycles on terminal ring.^{a,b,c,d}
50
51
52
53
54
55
56
57
58
59
60



Compd	R	H929 R10-1 IC ₅₀ (nM)	Aiolo s EC ₅₀ (nM)	Aiolo s Y _{min}	cLog P	α ₁	D _{2s}
13		1.7	0.1	6	3.6	101. 5	99. 1
14		2.8	0.1	5	3.5	100. 3	94. 7
29		7.4	0.7	11	2.8	97.7	90. 8
30		4.6	0.4	8	2.6	99.0	98. 0
31		3.5	0.4	9	1.8	25.2	32. 9
32		56	1.0	12	2.4	92.1	100
33		1.7	0.1	6	3.3	67	54. 5

^aAntiproliferative and Aiolos degradation values are the mean of at least three separate assay determinations, ^bSEM for data available in supplemental material, ^cY_{min} is the % protein remaining same comments 10 μM, after treatment for 4 h (see methods). ^dα₁ & D_{2s} reported as % inhibition @ 10 μM, ND, not determined.

Table 9. Comparison of functional activity between **13** and **33** for the D_{2S} dopamine agonist and α_1 adrenergic receptor.

	13	33
Receptor panel, Functional Activity:	α_1 IC ₅₀ = 14 nM D _{2S} EC ₅₀ = 16 nM	α_1 IC ₅₀ = 980 nM D _{2S} EC ₅₀ > 10,000nM

Having identified a compound with the desired combination of potent MM activity profile and off-target selectivity, we next established which enantiomer of **33** to further characterize. To understand the rate of epimerization that occurred at the chiral center in the pair of enantiomers **4** (*S*-enantiomer) and **76** (*R*-enantiomer), we measured the extent of their respective conversion over time. Racemization was examined in both aqueous buffer (pH 7.4) as well as in cell media. In either context, both compounds underwent full racemization over time. The racemization measurements for both the *R*-enantiomer and *S*-enantiomer in cell media are shown in Figure 7. Since racemization is complete at times sooner than the cellular readout (120 h), the proliferation assay could not be used to discriminate activity.







Figure 7. Measurement of racemization at the glutarimide chiral center in cell media. (a) Starting with the *R*-enantiomer, measurement of peak area over time which showed the loss of *R*-enantiomer and appearance of *S*-enantiomer. (b) Peak area measurement over time starting with the *S*-enantiomer.

1
2
3
4 The CRBN binding assay could be used to discriminate between enantiomers, since
5
6
7 the time course (4 h) is shorter than the racemization time for each enantiomer.
8
9
10
11 Measurement of the ability of each enantiomer to bind to CRBN was made at 4 h and
12
13
14 showed a large difference in binding affinity in which the *S*-enantiomer was the more
15
16
17 potent binder to CRBN (Figure 8).
18
19
20
21
22
23
24



44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 8. The CRBN binding affinity of the *R*-enantiomer (**76**) and *S*-enantiomer (**4**) measured at 4 h.

Since degradation for Aiolos could also be examined at time points prior to complete racemization, the activity dependence on each enantiomer was estimated in this format.

Evaluations were made as early as 45 min and included 1.5 and 3 h (Figure 9). The *S*-

1
2
3 enantiomer (**4**) was determined to be a more potent degrader, while also achieving
4
5
6
7 maximal levels of Aiolos destruction at lower concentrations than the *R*-enantiomer for all
8
9
10 time points. Since low level racemization occurred at the timepoints measured, it is
11
12
13 difficult to assign absolute activity to either enantiomer. However, taken together, the
14
15
16
17 Aiolos degradation and CRBN binding data supported the *S*-enantiomer as being more
18
19
20
21 active.
22
23
24
25





Figure 9. Measurement of Aiolos destruction by either enantiomer at 3 time points.

45 We hypothesized that the high activity displayed by compound **4** in the lenalidomide-
46 resistant cell line was connected to the rapid kinetics and depth of Aiolos degradation.
47
48 Thus, the governing activity determinant, particularly in situations of low CRBN cellular
49 concentration, would be two-fold: the potency of degradation, and importantly the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 degradation efficiency. When compared to the FDA approved drugs lenalidomide and
4
5
6
7 pomalidomide, **4** is able to degrade Aiolos more extensively, much faster, and at a lower
8
9
10 concentration (Figure 10).



28
29
30 **Figure 10.** Comparison of the Aiolos degradation curves at early time points for **4** (CC-92480) overlaid
31 with lenalidomide and pomalidomide. ePL degradation assay in DF15 cells.
32
33
34
35

36 The more efficient degradation profile of **4** correlated to superior induction of apoptosis
37 in myeloma cells (Figure 11b), and in the lenalidomide-resistant cells treated at
38
39 in myeloma cells (Figure 11b), and in the lenalidomide-resistant cells treated at
40 concentrations between 1 and 100 nM, nearly complete degradation of Ikaros and Aiolos
41
42 could be detected in 4 h (Figure 11a). In the same treatment arm, but at 72 h, western
43
44 blot analysis showed that treatment with **4** stabilized p27 and induced markers of
45
46 apoptosis (*e.g.* cleaved caspase). Comparatively, pomalidomide showed little to no effect
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 at similar concentrations and times. The measure of Caspase-3 induction was quantified
5
6
7 by live cell imaging and comparison could be drawn between **4**, lenalidomide, and
8
9
10 pomalidomide at concentrations from 1 nM to 1 μ M over 150 h (Figure 11b). The induction
11
12
13 of apoptosis seen for **4** was significant compared to lenalidomide or pomalidomide. For
14
15
16
17
18 example, at the lowest concentration of **4** tested (1 nM), the level of apoptosis was higher
19
20
21 than that observed at the highest concentration tested (1 μ M) for either lenalidomide or
22
23
24 pomalidomide.
25
26
27




Figure 11. a) Western blot analysis in H929 R10-1 cells showing the fast and deep degradation of Aiolos/Ikaros leads to superior induction of apoptosis. b) Comparison of apoptosis measured by caspase-3 induction in lenalidomide-refractory cells (H929 R10-1).

Next, we examined the pharmacokinetic properties of **4** in rat and monkey to support preclinical toxicology studies. The *in vitro* metabolic stability measured by compound incubation in S9 liver fractions for both human and rat was deemed acceptable, and when **4** was dosed in Sprague-Dawley rats as a 2 mg/kg solution intravenously, the observed *in vivo* clearance was found to be consistent with the predicted clearance from *in vitro* studies. When dosed orally as a suspension, **4** achieved a C_{max} of 3.2 μ M with an oral bioavailability of 38%. In the rat oral PK study, the percentage of racemization was measured and surprisingly determined to be less than 4% when compared to parent AUC or C_{max} levels. A similar finding was observed in monkey; the appearance of the *R*-enantiomer was less than 9% by either C_{max} or AUC comparison to parent (Table 11).

Table 11. Rat and Monkey ADME parameters for **4**.

Assay Parameter	4	76 (<i>R</i> -enantiomer)
CaCo-2; A-B / efflux ratio	20 / 1	


Solubility $\mu\text{g/mL}$ at pH 5.0	90	
Rat / Human S9 met. stability ^a	100 / 99	
Rat PK parameter		
iv CL ($\text{mL min}^{-1} \text{kg}^{-1}$) ^b	6.8 ± 1.0	
po C_{max} (μM) ^c	3.2 ± 0.5	0.06 ± 0.002
po T_{max} (h)	0.8 ± 0.3	
po AUC _(0-inf) ($\mu\text{M}\cdot\text{hr}$)	16.4 ± 6.8	0.5 ± 0.3
po F (%)	$38\% \pm 17$	
Amount of R-enantiomer formed in vivo (rat)		< 4% by AUC or C_{max}
Monkey PK parameter		
po C_{max} (μM) ^d	0.22 ± 0.08	0.016 ± 0.006
po AUC _(0-inf) ($\mu\text{M}\cdot\text{hr}$)	1.1 ± 0.3	0.1 ± 0.04
Amount of R-enantiomer formed in vivo (monkey)		< 9% by AUC or C_{max}

^a % remaining at 60 min. ^b Dosed 2 mg / kg in 15%DMA/50%PEG/35%D5W. ^c Dosed 10 mg/kg as a suspension in 0.5% CMC / 0.25% Tween-80 / water. ^d Dosed 3.0 mg/kg in 2%NMP / 20% Labrasol / 78% 50mM citrate buffer at pH=3.0.

Compound 4 was evaluated in efficacy models to assess tumor growth inhibition in tumor bearing mice. One model examined used the lenalidomide-resistant cell line H929 R10-1, where tumor-bearing mice were dosed orally for 21 days. Tumor volumes were determined prior to starting treatment and were considered the starting volumes. When tumors reached approximately 150 mm³, mice were randomized and treated once daily (*q.d.*) orally with vehicle control or various dosage strengths of 4. After treatment for 21

1
2
3 days, the tumor volumes were measured following the final day of dosing (Figure 12).

4
5
6
7 Both the 3 and 10 mg/kg doses gave near maximal response in this model, while the
8
9
10 lowest dose tested (1 mg/kg) showed 75% reduction in tumor volume by the end of the
11
12
13
14 study.



35
36 **Figure 12.** 21-day xenograft study of **4** dosed daily using the lenalidomide-resistant cell line H929 R10-
37
38 1.

39 40 41 42 CONCLUSION

43
44
45 The ability to influence protein homeostasis and its association with disease state
46
47
48 through targeted protein degradation has exciting implications for drug discovery. In
49
50
51 contrast to heterobifunctional protein degraders^{19,20,21} that require multiple elements
52
53
54
55
56
57
58
59
60

1
2
3 (target ligand, linker, ligase binder) to employ the CRBN E3 ligase system, CELMoDs
4
5
6
7 are relatively small molecular scaffolds that create an interaction hotspot on the surface
8
9
10 of CRBN that promotes direct ligase-target protein interactions.²² The CELMoDs
11
12
13
14 represent the first clinical examples of intentionally designed, targeted protein degraders.
15
16

17 Guided by the measurement of protein degradation as well as the antiproliferative
18
19
20 activity in lenalidomide-resistant cell lines, we discovered a novel series of aryl-piperazine
21
22
23
24 containing compounds with good in vitro selectivity that preferentially kill tumor versus
25
26
27 non-tumor cells. Within the aryl piperidine series, we identified candidates with low off-
28
29
30 target receptor binding profiles which we hypothesized would also lead to higher safety
31
32
33
34 margins *in vivo*. The phenotypic activity of the series was correlated to Aiolos degradation,
35
36
37 and in parallel, by optimizing for rapid and efficient protein degradation, we identified a
38
39
40 profile that led to strong induction of apoptosis in a low CRBN context (H929 R10-1 cells).
41
42
43
44

45 Unlike previously identified compounds, such as lenalidomide and pomalidomide, which
46
47
48 require higher concentrations and longer times to degrade protein substrates, CC-92480
49
50
51
52 (4) has a unique and rapid degradation profile: the enhanced efficiency to drive the
53
54
55 formation of the protein–protein interaction between Aiolos and cereblon, inducing
56
57
58
59
60

1
2
3 targeted docking to the CRL4-CRBN E3 ubiquitin ligase complex. The CC-92480-
4
5
6
7 dependent binding of Aiolos/Ikaros to CRBN leads to polyubiquitination and ultimately
8
9
10 proteasome-mediated degradation of protein. Rapid and extensive loss of Aiolos/Ikaros
11
12
13
14 in sensitive cells, such as multiple myeloma cells, results in apoptosis and subsequent
15
16
17 cell death.
18
19
20

21 During the SAR explorations described above, we observed variable levels of activity
22
23
24 and *in vitro* selectivity in response to minor structural changes. The subtleties of
25
26
27 substitution pattern SAR offer the opportunities to discover compounds across a varied
28
29
30 spectrum of degradation, potency, and selectivity, the molecular profiles of which when
31
32
33
34 adjusted properly, have the potential to transform serious diseases and create new
35
36
37
38 landmark therapies.
39
40
41
42
43
44

45 EXPERIMENTAL SECTION

46
47
48

49 **General.** Compounds were named using ChemDraw Ultra. All materials were
50
51
52 obtained from commercial sources and used without further purification, unless otherwise
53
54
55 noted. Chromatography solvents were HPLC grade and used as purchased. All air-
56
57
58
59
60

1
2
3 sensitive reactions were carried out under a positive pressure of an inert nitrogen
4
5
6 atmosphere. Chemical shifts (δ) are reported in ppm downfield of TMS and coupling
7
8 constants (J) are given in Hz. Thin Layer Chromatography (TLC) analysis was performed
9
10 on Whatman thin layer plates. The purity of final tested compounds was $\geq 95\%$ as
11
12 determined by HPLC using the following method: gradient (5-95% ACN + 0.075% formic
13
14 acid in water + 0.1% formic acid over 8 min, followed by 95% ACN + 0.075% formic acid
15
16 for 2 min); flow rate 1 mL/min, column Phenomenex Luna 5 μ PFP(2) 100A (150 mm x
17
18 4.60 mm). Elemental analysis was performed at Robertson Microlit Laboratories,
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ledgewood, New Jersey.

Synthesis.

2-(*tert*-Butoxycarbonylamino) -5-methoxy-5-oxo-pentanoic acid (6). *Step A.* To a suspension of 2-aminopentanedioic acid (**5**) (250 g, 1.70 mol) in dry methanol (2.5 L) under N₂ was added TMSCl (277 g, 2.55 mol) over 30 min. The resulting clear solution was stirred at RT for 30 min. The reaction mixture was carried forward to the next step without further work-up. ¹H NMR (400 MHz, CD₃OD) δ 4.17 – 4.15 (m, 1H), 3.71 (s, 3H), 2.70 – 2.60 (m, 2H), 2.33 – 2.25 (m, 2H).

1
2
3
4 *Step B.* To the solution from the previous step were added TEA (275 g, 2.72 mol) and
5
6
7 Boc₂O (447.35 g, 2.05 mol). The reaction mixture was stirred at 25 °C for 2 h. The solution
8
9
10 was concentrated to dryness, then H₂O (2.5 L) was added to dissolve the residue. The
11
12
13 resulting aqueous phase was washed with EtOAc (200 mL), then acidified to pH = 3 by
14
15
16 HCl (1 N) and extracted with EtOAc (3 x 1 L). The combined organic layers were washed
17
18
19 with brine (800 mL), dried over Na₂SO₄, filtered, and concentrated to give **6** (250 g, 957
20
21
22 mmol, 56% yield over 2 steps) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 4.18 – 4.11
23
24
25 (m, 1H), 3.69 (s, 3H), 2.48 – 2.43 (m, 2H), 2.21 – 2.15 (m, 1H), 1.95 – 1.91 (m, 1H), 1.46
26
27
28 (s, 9H).

29
30
31
32
33
34
35 **Methyl 5-amino-4-(tert-butoxycarbonyl amino)-5-oxo-pentanoate (7).** To a solution of **6**
36
37
38 (200 g, 765 mmol) in dioxane (1.5 L) were added Boc₂O (267 g, 1.22 mol) and pyridine
39
40
41 (121 g, 1.53 mol). After the reaction mixture was stirred at 25 °C for 30 min, NH₄HCO₃
42
43
44 (182 g, 2.30 mol) was added to the mixture and stirred for additional 16 h at 25 °C. The
45
46
47 organic solvent was removed under reduced pressure. The residue was acidified by HCl
48
49
50 (6 M) to pH = 3 and then extracted with EtOAc (3 x 800 mL). The combined organic layer
51
52
53
54
55
56
57
58
59
60

1
2
3
4 was washed with brine (800 mL), dried over Na₂SO₄, filtered, and concentrated to give **7**
5
6
7 (180 g, 692 mmol, 90% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 6.51 (s, 1H),
8
9
10 5.94 (s, 1H), 5.43 (s, 1H), 4.21 (s, 1H), 3.63 (s, 3H), 2.59 – 2.40 (m, 2H), 2.15 – 2.11 (m,
11
12
13 1H), 1.94 – 1.90 (m, 1H), 1.42 (s, 9H).
14
15
16
17

18 **Methyl 4,5-diamino-5-oxo-pentanoate hydrochloride (8)**. A mixture of **7** (180 g, 692 mmol)
19
20
21 and HCl/EtOAc (300 mL, 4 M) was stirred at 25 °C for 12 h. The precipitated solid was
22
23
24 collected by vacuum filtration and washed with EtOAc (500 mL) to give **8** (130 g, 661
25
26
27 mmol, 95% yield) as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 4.00 – 3.96 (m, 1H),
28
29
30 3.70 (s, 3H), 2.59 – 2.52 (m, 2H), 2.22 – 2.13 (m, 2H).
31
32
33
34
35

36 **Methyl 2-(bromomethyl)-3-[tert-butyl(dimethyl)silyl]oxy-benzoate (10)**. *Step A*. H₂SO₄
37
38
39 (129.07 g, 1.32 mol) was added dropwise to a mixture of 3-hydroxy-2-methyl-benzoic acid
40
41
42
43 (**9**) (500 g, 3.29 mol) in MeOH (5.00 L) over 30 min. The reaction mixture was stirred at
44
45
46
47 65 °C for 17 h. The solvent was removed under reduced pressure. To the remaining
48
49
50
51 residue was added water (15 L) slowly at room temperature. A brown solid was formed
52
53
54 and the suspension was stirred in an ice bath for 30 min. The solid was collected by
55
56
57
58
59
60

1
2
3 vacuum filtration, washed with water (5 L), and dried to give methyl 3-hydroxy-2-methyl-
4
5
6
7 benzoate (484.5 g, 2.92 mol, 88.7% yield) as a light brown solid. ^1H NMR (400 MHz
8
9
10 CD_3OD) δ 7.25 (d, J = 8.0 Hz, 1H), 7.05 (t, J = 8.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 3.85
11
12
13
14 (s, 3H), 2.35 (s, 3H).
15
16
17

18 *Step B.* To a 10 L three-neck flask equipped with mechanical stir bar and thermometer,
19
20
21 were added DCM (5 L), methyl 3-hydroxy-2-methyl-benzoate (475.00 g, 2.86 mol) and
22
23
24 imidazole (389.42 g, 5.72 mol, 385.56 mL). Chloro-dimethyl-(1-methyl-1-methyl-
25
26
27 ethyl)silane (470.99 g, 3.15 mol) was added to the above solution in portions. After the
28
29
30 addition, the mixture was stirred at 25 °C for 1 h. The reaction mixture was quenched with
31
32
33 saturated NaHCO_3 (400 mL), extracted with DCM (2.5 L), and washed with cold water
34
35
36 (2.5 L) and brine (2.5 L). The combined organic layer was dried over Na_2SO_4 and filtered.
37
38
39
40
41
42 The filtrate was concentrated and the remaining residue was purified by silica gel column
43
44
45 chromatography to give methyl 3-[tert-butyl(dimethyl)silyl]-oxy-2-methyl-benzoate (605.0
46
47
48
49 g, 2.16 mol, 75.4% yield) as a brown oil. ^1H NMR (400 MHz, CDCl_3) δ 7.44 (d, J = 7.50
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Hz, 1H), 7.10 (t, $J = 7.94$ Hz, 1H), 6.94 (d, $J = 7.94$ Hz, 1H), 3.89 (s, 3H), 2.43 (s, 3H),
4
5
6
7 1.04 (s, 9H), 0.23 (s, 6H).
8
9

10
11 *Step C.* To a solution of methyl 3-[tert-butyl(dimethyl)silyl]oxy-2-methyl-benzoate (342.00
12
13 g, 1.22 mol) in EtOAc (3.40 L) was added AIBN (6.01 g, 36.60 mmol) and NBS (249.61
14
15 g, 1.40 mol) at 20 °C to give a suspension. The suspension was stirred and refluxed at
16
17
18 65 °C for 2 h under a tungsten lamp. The reaction was cooled to RT, washed with
19
20
21 aqueous Na₂SO₃ (3 L), brine (3 x 1500 mL), dried over Na₂SO₄, filtered, and concentrated
22
23
24 to give **10** (431.2 g, 1.20 mol, 98.5% yield) as a brown oil. ¹H NMR (400 MHz, CDCl₃) δ
25
26
27
28 7.52 (d, $J = 7.94$ Hz, 1H), 7.21 – 7.27 (m, 1H), 6.99 (d, $J = 7.94$ Hz, 1H), 5.03 (s, 2H),
29
30
31
32 3.94 (s, 3H), 1.07 (s, 9H), 0.31 (s, 6H).
33
34
35
36
37
38
39

40 **Methyl 5-amino-4-[4-[hydroxy-1-oxo-isoindolin-2-yl]-5-oxo-pentanoate (11).** *Step A.* To a
41
42 stirred solution of **8** (74.5 g, 379 mmol) in ACN (2.50 L) was added **10** (125 g, 348 mmol).
43
44
45 To the suspension was added DIEA (89.9 g, 696 mmol) through an addition funnel over
46
47
48 10 min and then the mixture was stirred at 60 °C for 16 h. The reaction mixture was diluted
49
50
51 with EtOAc (1 L), and washed with HCl (1N, 1 L), aqueous NaHCO₃ (saturated, 1 L) and
52
53
54
55
56
57
58
59
60

1
2
3
4 brine (1 L). The organic layer was concentrated to give crude methyl 5-amino-4-[4-[tert-
5
6
7 butyl(dimethyl)silyl]oxy-1-oxo- isoindolin-2-yl]-5-oxo-pentanoate (108 g, 266 mmol, 76%
8
9
10 yield) as a light yellow solid. MS (ESI) m/z 407.3 [M+1]⁺.
11
12
13

14
15 *Step B.* To a stirred cold solution of methyl 5-amino-4-[4-[tert-butyl(dimethyl)silyl]oxy-1-
16
17
18 oxo-isoindolin-2-yl]-5-oxo-pentanoate (108 g, 266 mmol) in DMF (350 mL) was added
19
20
21 K₂CO₃ (14.7 g, 106 mmol) in H₂O (40 mL) by portions over 5 min. The resulting reaction
22
23
24
25 mixture was stirred at 15 °C for 15 h. The reaction mixture was cooled to 0 °C and HCl
26
27
28 (12 M, 15 mL) was slowly added. Acetonitrile (200 mL) was added to the mixture and a
29
30
31 precipitate solid formed. The suspension was stirred at RT for 10 min and filtered. The
32
33
34
35 filter cake was washed with EtOAc (200 mL x 5) to give desired product (55 g). The filtrate
36
37
38
39 was concentrated under reduced pressure to give a crude product (100 g) which was
40
41
42
43 dissolved in DCM (1 L) and left to stand at 15 °C for 16 h. A white solid was formed which
44
45
46
47 was collected by filtration to give an additional 5 g of desired product. A total 60 g of 11
48
49
50 (60 g, 205 mmol, 77% yield) was obtained as a white solid. ¹H NMR (400 MHz, DMSO-
51
52
53 *d*₆) δ 7.58 (s, 1H), 7.31 (t, *J* = 8.0 Hz, 1H), 7.19 – 7.14 (m, 2H), 7.01 (d, *J* = 7.6 Hz, 1H),
54
55
56
57
58
59
60

1
2
3 4.75 – 4.71 (m, 1H), 4.50 (d, $J = 17.6$ Hz, 1H), 4.32 (d, $J = 17.6$ Hz, 1H), 3.51 (s, 3H),
4
5
6
7 2.29 – 2.18 (m, 3H), 2.09 – 1.99 (m, 1H).
8
9

10
11 **Methyl-5-amino-4-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]-5-oxo-**

12 **pentanoate (12a).** A mixture of 1,4-bis(bromomethyl)benzene (67.7 g, 257 mmol), K_2CO_3

13
14
15 (11.8 g, 85.5 mmol) and methyl 5-amino-4-(4-hydroxy-1-oxo- isoindolin-2-yl)-5-oxo-

16
17
18
19
20
21
22 pentanoate (25 g, 85.5 mmol) in ACN (1 L) were stirred at 60 °C for 16 h. The reaction

23
24
25 mixture was cooled to RT and filtered. The filtrate was concentrated and purified by silica

26
27
28
29 gel column chromatography to afford **12a** (25.5 g, 54 mmol, 63% yield) as a white solid.

30
31
32 1H NMR (400 MHz $DMSO-d_6$) δ 7.59 (s, 1H), 7.50 – 7.44 (m, 5H), 7.32 – 7.28 (m, 2H),

33
34
35
36 7.19 (s, 1H), 5.26 (s, 2H), 4.79 – 4.71 (m, 3H), 4.55 (d, $J = 17.6$ Hz, 1H), 4.43 (d, $J = 17.6$

37
38
39 Hz, 1H), 3.52 (s, 3H), 2.30 – 2.19 (m, 3H), 2.10 – 2.08 (m, 1H).
40
41
42

43 **4-Carbamoyl-4-[4-(4-chloromethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-butyric**

44 **acid methyl ester (12b).** Polymer-supported triphenylphosphine (1.6 mmol/g, 10 g, 16

45
46
47
48
49 mmol) was added to a stirred suspension of **11** (2.49 g, 8.52 mmol) in THF (100 mL) at 0

50
51
52
53
54 °C, followed by diisopropyl diazene-1,2-dicarboxylate (3.36 mL, 17.04 mmol). After
55
56
57
58
59
60

1
2
3 stirring for 30 min, (4-(chloromethyl) phenyl)methanol (2.00 g, 12.78 mmol) was added.
4
5

6
7 The mixture was stirred for 1 h then filtered. The resin was washed with methanol (3 x 30
8

9
10 mL) and DCM (3 x 30 mL). The combined filtrate was concentrated under reduced
11

12
13 pressure to give an oil, which was purified by silica gel column chromatography to give
14

15
16 **12b** as an oil (3.38 g, 92% yield). ¹H NMR (DMSO-*d*₆) δ 7.58 (d, *J* = 0.4 Hz, 1H), 7.41 –
17

18
19 7.54 (m, 5H), 7.25 – 7.35 (m, 2H), 7.19 (d, 1H), 5.26 (s, 2H), 4.78 (s, 2H), 4.73 (dd, *J* =
20

21
22 4.8, 10.3 Hz, 1H, NCH), 4.35 – 4.62 (m, 2H), 3.50 (s, 3H), 1.97 – 2.35 (m, 4H).
23
24
25
26
27

28
29 **3-(4-((4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**

30
31 **yl)piperidine-2,6-dione (13).** *Step A.* A solution of **12a** (28.5 g, 60.0 mmol) in THF (720
32

33
34 mL) was cooled in a dry ice/acetone bath to -78 °C. While stirring, t-BuOK (7.4 g, 66.0
35

36
37 mmol) was added in one portion to the clear solution. Stirring continued for an additional
38

39
40 2 h at -78 °C. A cooled 1N aqueous solution of HCl (260 mL) was added to the reaction
41

42
43 mixture while maintaining a temperature of -78 °C. The mixture was concentrated under
44

45
46 reduced pressure until a white slurry remained. The white slurry was diluted with water
47

48
49 (250 mL) and then collected by filtration. The filter cake was washed with water (250 mL)
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 and dried, then washed with EtOAc (250 mL) to give 3-(4-((4-(bromomethyl)benzyl)oxy)-
5
6
7 1-oxoisindolin-2-yl)piperidine-2,6-dione (24.7 g, 55.7 mmol, 93% yield) as a light yellow
8
9
10 solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.95 (s, 1H), 7.51 – 7.41 (m., 5H), 7.35 – 7.28 (m,
11
12
13 2H), 5.23 (s, 2H), 5.12 – 5.07 (m, 1H), 4.70 (s, 2H), 4.41 (d, *J* = 17.6 Hz, 1H), 4.25 (d, *J*
14
15 = 17.6 Hz, 1H), 2.90 – 2.84 (m, 1H), 2.58 – 2.53 (m, 1H), 2.44 – 2.41 (m, 1H), 1.98 – 1.95
16
17
18 (m, 1H).
19
20
21
22
23
24

25 *Step B.* 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione
26
27 (17.44 g, 39.4 mmol) was placed in a flask with 1-(2,4-difluorophenyl)piperazine (7.80 g,
28
29 39.4 mmol), DIEA (20.62 mL, 118 mmol), and ACN (200 mL). The reaction mixture was
30
31
32 stirred at 40 °C for 18 h. Volatile organics were removed under reduced pressure to give
33
34
35 an off-white solid. The solid was taken up in DMSO and purified using reverse-phase
36
37
38 semi-preparative HPLC. Fractions containing the desired product were combined and
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

give a white solid. The solid was slurried in water and filtered to give **13** (10.1 g, 18.02

1
2
3 mmol, 45.8% yield, HPLC purity >99%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ
4 10.97 (s, 1H), 7.43 – 7.52 (m, 3H), 7.30 – 7.39 (m, 4H), 7.17 (ddd, *J* = 2.81, 9.20, 12.44
5
6
7 Hz, 1H), 7.01 – 7.10 (m, 1H), 6.94 – 7.01 (m, 1H), 5.24 (s, 2H), 5.11 (dd, *J* = 5.14, 13.33
8
9
10 Hz, 1H), 4.38 – 4.46 (m, 1H), 4.22 – 4.30 (m, 1H), 3.54 (s, 2H), 2.85 – 3.01 (m, 5H), 2.59
11
12
13 (br s, 5H), 2.38 – 2.48 (m, 1H), 1.92 – 2.03 (m, 1H). MS (ESI) *m/z* 561.2[M+1]⁺. Anal.
14
15
16
17
18 Calcd for C₃₁H₃₀F₂N₄O₄: C, 66.42; H, 5.39; N, 9.99. Found: C, 65.60; H, 5.47; N 9.82;
19
20
21
22
23
24
25 Karl Fischer = 0.25%.

26
27
28
29 **3-(4-((4-((4-(4-Fluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**
30
31
32 **yl)piperidine-2,6-dione (14).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132

1
2
3 Hz, 2H), 7.03 – 7.12 (m, 2H), 6.87 – 7.00 (m, 2H), 5.28 (s, 2H), 5.10 (dd, $J = 13.08, 5.27$
4
5
6 Hz, 1H), 4.32 – 4.46 (m, 3H), 4.25 (d, $J = 17.57$ Hz, 1H), 3.69 (d, $J = 12.89$ Hz, 2H), 3.07
7
8
9
10 – 3.22 (m, 2H), 2.96 – 3.07 (m, 2H), 2.89 (ddd, $J = 17.67, 13.18, 5.08$ Hz, 1H), 2.50 – 2.60
11
12
13 (m, 1H), 2.34 – 2.45 (m, 1H), 1.89 – 2.01 (m, 1H); MS (ESI) m/z 543.7 [M+1]⁺.
14
15
16

17 **3-(4-((4-((4-(3-Fluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**

18
19
20 **yl)piperidine-2,6-dione (15).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
yl)piperidine-2,6-dione (0.130 g, 0.293 mmol) in ACN (3 mL) was added DIEA (0.102 mL,
0.587 mmol) followed by 1-(3-fluorophenyl)piperazine (0.074 g, 0.411 mmol). The
reaction mixture was stirred overnight at RT. The reaction was concentrated under
reduced pressure and the residue purified by HPLC to give **15** (0.078 g, 0.144 mmol, 49%
yield, HPLC purity >96%) ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 10.39 (br. s.,
2H) 7.58 (s, 4H), 7.47 (t, $J = 7.81$ Hz, 1H), 7.31 (dd, $J = 7.81, 3.91$ Hz, 2H), 7.24 (q, $J =$
8.07 Hz, 1H), 6.72 – 6.84 (m, 2 H) 6.61 (t, $J = 8.40$ Hz, 1 H) 5.28 (s, 2 H), 5.10 (dd, $J =$
13.08, 4.88 Hz, 1H), 4.32 – 4.45 (m, 3H), 4.20 – 4.29 (m, 1H), 3.86 (d, $J = 12.11$ Hz, 2H),
3.00 – 3.20 (m, 4H), 2.81 – 2.98 (m, 1H), 2.51 – 2.61 (m, 1H), 2.37 – 2.44 (m, 1H), 1.89 –
2.03 (m, 1H); MS (ESI) m/z 543.8 [M+1]⁺.

3-(4-((4-((4-(2-Fluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-

yl)piperidine-2,6-dione (16). To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (0.119 g, 0.268 mmol) in ACN (3 mL) was added DIEA (0.094 mL, 0.537 mmol) followed by 1-(2-fluorophenyl)piperazine (0.068 g, 0.376 mmol). The reaction mixture was stirred overnight at RT. The reaction was concentrated, and the residue was purified by HPLC to give **16**. (0.026 g, 0.048 mmol, 18% yield, HPLC purity >99%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1H), 7.57 – 7.68 (m, 4H), 7.46 – 7.53 (m, 1H), 7.31 – 7.38 (m, 2H), 7.00 – 7.23 (m, 4H), 5.31 (s, 2H), 5.12 (dd, *J* = 5.07, 13.27 Hz, 1H), 4.36 – 4.49 (m, 3H), 4.24 – 4.33 (m, 1H), 3.49 (br d, *J* = 12.47 Hz, 2H), 3.39 (br d, *J* = 11.74 Hz, 2H), 3.18 – 3.30 (m, 2H), 3.07 – 3.18 (m, 2H), 2.85 – 2.99 (m, 1H), 2.54 – 2.63 (m, 1H), 2.38 – 2.48 (m, 1H), 1.94 – 2.05 (m, 1H); MS (ESI) *m/z* 543.6 [M+1]⁺.

3-(4-((4-((4-(2,6-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-

yl)piperidine-2,6-dione (17). To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (0.131 g, 0.296 mmol) in ACN (3 mL) was added DIEA (0.103 mL, 0.591 mmol) followed by 1-(2,6-difluorophenyl)piperazine (0.082 g, 0.414 mmol). The reaction mixture was stirred overnight at RT. The reaction was concentrated under

1
2
3 reduced pressure and the residue was purified by HPLC to give **17**. (0.080 g, 0.143 mmol,
4
5
6 48.3% yield, HPLC purity >97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.97 (s, 1H),
7
8 7.54 – 7.66 (m, 4H), 7.47 (t, *J* = 7.81 Hz, 1H), 7.28 - 7.35 (m, 2 H), 6.99 - 7.18 (m, 3H),
9
10
11 5.27 (s, 2H), 5.09 (dd, *J* = 13.28, 5.08 Hz, 1H), 4.32 – 4.48 (m, 3H), 4.15 – 4.32 (m, 1H),
12
13
14 3.39 – 3.53 (m, 2H), 3.22 – 3.31 (m, 3H) 3.06 – 3.21 (m, 2H), 2.81 – 2.95 (m, 1H), 2.55
15
16
17 (d, *J* = 16.79 Hz, 1H), 2.41 (dd, *J* = 13.28, 4.69 Hz, 1H), 1.90 – 2.01 (m, 1H); MS (ESI)
18
19
20
21
22
23
24
25 *m/z* 561.2 [M+1]⁺.
26
27

28 **3-(4-((4-((4-(2,4-Dichlorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**
29
30
31 **yl)piperidine-2,6-dione (18)**. To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136

1
2
3
4 4.38 (dd, $J = 11.33, 5.86$ Hz, 3H), 4.16 – 4.26 (m, 1H), 3.34 (s, 2H), 3.37 (s, 2H), 3.17 (d,
5
6
7 $J = 10.55$ Hz, 1H), 2.91 – 3.04 (m, 1H), 2.47 – 2.56 (m, 2H) 1.80 – 2.00 (m, 1H); MS (ESI)
8
9
10 m/z 595.1 [M+1]⁺.

11
12
13
14 **3-(4-((4-((4-Chlorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**

15
16
17 **yl)piperidine-2,6-dione, HCl (19).** 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisindolin-2-

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
yl)piperidine-2,6-dione (0.282 g, 0.636 mmol) was placed in a flask with 1-(4-

chlorophenyl)piperazine (0.125 g, 0.636 mmol), DIEA (0.222 mL, 1.271 mmol), and ACN

(6.0 mL). The reaction mixture was heated to 40 °C for 18 h. The reaction mixture was

filtered and the residue was purified by HPLC to give a white solid. The solid was taken

up in methanol and 6N HCl was added (~3 drops) until the solid fully went into solution.

Volatile organics were removed under reduced pressure to give **19** (0.240 g, 0.403 mmol,

63.4% yield, HPLC purity >99%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98

(s, 1H), 7.64 – 7.70 (m, 2H), 7.56 – 7.62 (m, 2H), 7.46 – 7.53 (m, 1H), 7.32 – 7.36 (m, 2H),

7.26 – 7.31 (m, 2H), 6.93 – 7.02 (m, 2H), 5.30 (s, 2H), 5.12 (dd, $J = 5.14, 13.33$ Hz, 1H),

4.41 – 4.49 (m, 1H), 4.38 (br d, $J = 5.01$ Hz, 2H), 4.23 – 4.33 (m, 1H), 3.80 (br d, $J = 10.27$

1
2
3 Hz, 2H), 3.35 (br d, $J = 8.80$ Hz, 2H), 3.05 – 3.22 (m, 4H), 2.84 – 2.98 (m, 1H), 2.58 (br d,
4
5
6
7 $J = 17.48$ Hz, 1H), 2.38 – 2.48 (m, 1H), 1.94 – 2.05 (m, 1H); MS (ESI) m/z 559.2 $[M+1]^+$.
8
9

10
11 **3-(4-((4-((4-(4-Methoxyphenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**

12 **yl)piperidine-2,6-dione (20).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
13
14
15 **yl)piperidine-2,6-dione (20).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
16
17
18
19 **yl)piperidine-2,6-dione (0.119 g, 0.268 mmol)** in ACN (3 mL) was added DIEA (0.094 mL,
20
21
22 0.537 mmol) followed by 1-(4-methoxyphenyl)piperazine (0.072 g, 0.376 mmol). The
23
24
25
26 reaction mixture was stirred overnight at RT. The reaction was concentrated under
27
28
29 reduced pressure and the residue was purified by HPLC to give **20**. (0.125 g, 0.225 mmol,
30
31
32 84% yield, HPLC purity >96%). ^1H NMR (400 MHz, DMSO- d_6) δ 10.97 (s, 1H), 7.63 –
33
34
35
36 7.68 (m, 2H), 7.57 – 7.62 (m, 2H), 7.46 – 7.53 (m, 1H), 7.31 – 7.37 (m, 2H), 6.90 – 6.96
37
38
39 (m, 2H), 6.82 – 6.88 (m, 2H), 5.31 (s, 2H), 5.12 (dd, $J = 5.14, 13.20$ Hz, 1H), 4.42 – 4.50
40
41
42 (m, 1H), 4.39 (br d, $J = 4.40$ Hz, 2H), 4.28 (d, $J = 17.36$ Hz, 1H), 3.69 (s, 3H), 3.62 (br d,
43
44
45
46 $J = 12.96$ Hz, 2H), 3.36 (br d, $J = 11.49$ Hz, 2H), 3.10 – 3.23 (m, 2H), 2.98 – 3.07 (m, 2H),
47
48
49 2.85 – 2.97 (m, 1H), 2.58 (br d, $J = 16.99$ Hz, 1H), 2.38 – 2.48 (m, 1H), 1.94 - 2.05 (m,
50
51
52
53 1H); MS (ESI) m/z 555.2 $[M+1]^+$.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 **3-(1-Oxo-4-((4-((4-phenylpiperazin-1-yl)methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-**
9
10
11 **dione (21).** To a solution of 3-(4-(4-(bromomethyl)benzyloxy)-1-oxoisindolin-2-
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
yl)piperidine-2,6-dione (0.50 g, 1.13 mmol) in ACN (15 mL) was added DIEA (0.373 mL,
2.256 mmol) followed by 1-phenylpiperazine (0.257 mL, 1.692 mmol) at RT. The mixture
was stirred at RT overnight. The solvent was evaporated and the resulting white solid was
stirred in water (50 mL) and extracted with DCM (2 x 80 mL). The combined organic
phases were back-washed with water (50 mL), brine (30 mL), and evaporated to a white
solid. The solid was stirred in ACN (8 mL) at 50 °C for 1 h then collected by filtration and
dried under vacuum oven to give **21** as a white solid (0.316 g, 53% yield, HPLC purity
>95%). ¹H NMR (DMSO-*d*₆) δ 10.98 (s, 1H), 7.42 – 7.55 (m, 3H), 7.28 – 7.41 (m, 4H),
7.15 – 7.25 (m, 2H), 6.91 (d, *J* = 7.9 Hz, 2H), 6.76 (t, *J* = 7.3 Hz, 1H), 5.20 – 5.30 (m, 2H),
5.11 (dd, *J* = 5.1, 13.2 Hz, 1H), 4.20 – 4.48 (m, 2H), 3.50 – 3.62 (m, 2H), 3.12 (t, *J* = 5.1
Hz, 4H), 2.83 – 2.99 (m, 1H), 2.53 – 2.65 (m, 2H), 2.36 – 2.47 (m, 1H), 1.92-2.06 (m, 1H);
¹³C NMR (DMSO-*d*₆) δ 22.36, 31.21, 45.09, 48.18, 51.58, 52.52, 61.71, 69.41, 114.97,

1
2
3
4 115.24, 115.35, 118.76, 127.68, 128.86, 129.01, 129.82, 129.95, 133.32, 135.30, 137.93,
5
6
7 150.98, 153.50, 168.01, 170.98, 172.83; MS (ESI) m/z 525 $[M+1]^+$; Anal Calcd for
8
9
10 $C_{31}H_{32}N_4O_4$: C, 70.97; H, 6.15; N, 10.68. Found: C, 70.69; H, 6.01; N, 10.49; mp 195 –
11
12
13
14 197°C.
15
16
17

18 **3-(4-((4-((4-Isopropylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-**
19
20
21 **2,6-dione (22)**. To a solution of the mixture (~1:1) of 3-(4-(4-(bromomethyl)benzyloxy)-1-
22
23
24
25 oxoisindolin-2-yl)piperidine-2,6-dione (0.25 g, 0.564 mmol) and 3-(4-(4-
26
27
28 (chloromethyl)benzyloxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (0.225 g, 0.564
29
30
31
32 mmol) in ACN was added DIEA (0.292 g, 2.256 mmol) followed by 1-isopropylpiperazine
33
34
35 (0.174 g, 1.354 mmol) at RT. The mixture was stirred at RT overnight. The solvent was
36
37
38 removed under reduced pressure. The resulting white solid was stirred in water (40 mL)
39
40
41
42 and extracted with DCM (2 x 40 mL). The combined organic phases were washed with
43
44
45
46 water (50 mL) and then evaporated under reduced pressure to give a white oily solid. The
47
48
49
50 solid was stirred in diethyl ether (25 mL) overnight. The suspension was collected by
51
52
53
54 filtration to give an off-white solid, which was suspended in ACN (4 mL) and stirred in a
55
56
57
58
59
60

1
2
3
4 50 °C oil bath for 30 min. The suspension was collected by filtration to give **22** as a white
5
6
7 solid (0.187 g, 34% yield, HPLC purity >95%). ¹H NMR (DMSO-*d*₆) δ 10.97 (s, 1H), 7.38
8
9
10 – 7.54 (m, 3H), 7.26 – 7.36 (m, 4H), 5.22 (s, 2H), 5.11 (dd, *J* = 5.2, 13.1 Hz, 1H), 4.20 –
11
12
13 4.47 (m, 2H), 3.44 (s, 2H), 3.44 (s, 2H), 2.82 – 2.99 (m, 1H), 2.53 – 2.67 (m, 2H), 2.21 –
14
15
16 2.48 (m, 9H), 1.91 – 2.04 (m, 1H), 0.94 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (DMSO-*d*₆) δ 18.22,
17
18
19
20
21 22.36, 31.21, 45.09, 47.95, 51.58, 53.04, 53.55, 61.81, 69.44, 114.97, 115.23, 127.62,
22
23
24 128.86, 129.81, 129.95, 133.31, 135.13, 138.24, 153.51, 168.01, 170.98, 172.83; Anal
25
26
27
28 Calcd for C₂₈H₃₄N₄O₄+0.1H₂O: C, 68.30; H, 7.00; N, 11.38. Found: C, 68.21; H, 6.61; N,
29
30
31 11.19; mp 193 – 195°C.
32
33
34
35

36 **3-(4-((4-((4-Isopropylpiperidin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-**
37
38
39 **2,6-dione (23).** *Step A.* To a solution of **12a** (0.5 g, 1.052 mmol) in ACN, was added 4-
40
41
42 isopropylpiperidine (0.294 g, 2.314 mmol). The mixture was stirred at RT overnight. The
43
44
45
46 reaction mixture was concentrated under reduced pressure. The resulting oil was taken
47
48
49
50 up in EtOAc (15 mL) and extracted with water (20 mL). The organic layer was washed
51
52
53
54 with brine (10 mL), dried over Na₂SO₄ and concentrated to give methyl 5-amino-4-(4-(4-
55
56
57
58
59
60

1
2
3
4 ((4-isopropylpiperidin-1-yl)methyl)benzyloxy)-1-oxoisindolin-2-yl)-5-oxopentanoate as
5
6
7 an oil.
8
9

10
11 *Step B.* To a solution of methyl 5-amino-4-(4-(4-((4-isopropylpiperidin-1-
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
yl)methyl)benzyloxy)-1-oxoisindolin-2-yl)-5-oxopentanoate (0.548 g, 1.05 mmol) in THF,
was added *t*BuOK (0.12 g, 1.069 mmol) at 0 °C. The mixture was stirred at 0 °C for 30
min. The reaction was quenched by adding 2 mL of HCl (1N) and 5 mL of NaHCO₃
(saturated) followed by EtOAc (20 mL) and water (10 mL). The mixture was extracted in
EtOAc and the organic layer was washed with water (10 mL), brine (10 mL), and
concentrated. The resulting solid was purified by HPLC to give **23** as a white solid (65
mg, 13% yield, HPLC purity >96%). ¹H NMR (DMSO-*d*₆) δ 10.97 (s, 1H), 7.38 – 7.54 (m,
3H), 7.25 – 7.37 (m, 4H), 5.22 (s, 2H), 5.11 (dd, *J* = 5.1, 13.2 Hz, 1H), 4.19 – 4.47 (m, 2H),
3.40 – 3.46 (br. s, 2H), 2.88 – 3.00 (m, 1H), 2.74 – 2.88 (m, 2H), 2.53 – 2.63 (m, 1H),
2.36 – 2.47 (m, 1H), 1.93 – 2.04 (m, 1H), 1.76 – 1.92 (m, 2H), 1.51 – 1.63 (m, 2H), 1.31 –
1.47 (m, 1H), 1.07 – 1.25 (m, 2H), 0.90 – 1.06 (m, 1H), 0.83 (d, *J* = 6.8 Hz, 6H); ¹³C NMR
(DMSO-*d*₆) 19.66, 22.36, 28.88, 31.21, 31.94, 41.84, 45.09, 51.58, 53.63, 62.13, 69.45,

1
2
3 114.97, 115.21, 127.61, 128.80, 129.81, 129.95, 133.31, 135.04, 153.51, 168.01, 170.96,
4
5
6
7 172.82; MS (ESI) m/z 490.3 [M+1]⁺; Anal Calcd for C₂₉H₃₅N₃O₄+0.4 H₂O: C, 70.11; H,
8
9
10 7.26; N, 8.46; Found: C, 70.10; H, 7.37; N, 8.36. mp: 124-126°C.

14
15 **3-(1-Oxo-4-((4-((4-(trifluoromethyl)piperidin-1-yl)methyl)benzyl)oxy)isoindolin-2-**

16
17
18 **yl)piperidine-2,6-dione (24).** *Step A.* In a flask, tert-butyl 5-amino-2-(4-hydroxy-1-
19
20
21
22 oxoisoindolin-2-yl)-5-oxopentanoate (3 g, 8.79 mmol) and triphenyl phosphine on
23
24
25 polystyrene (1.6 mmol/g resin, 10.99 g, 17.59 mmol) were slurried in THF (100 mL, 1220
26
27
28 mmol) at RT. The resin was allowed to swell with gentle stirring for 5 min then the mixture
29
30
31
32 was cooled in an ice bath at 0°C. To the mixture, DIAD (3.42 mL, 17.59 mmol) was added
33
34
35
36 using a syringe in a rapid dropwise fashion. After 10 min, (4-(chloromethyl)
37
38
39 phenyl)methanol (2.066 g, 13.19 mmol) was added as a solid in one portion. The ice bath
40
41
42
43 was removed and the mixture was stirred at RT for 6 h. The resin was removed by suction
44
45
46
47 filtration and rinsed with successive washes of DCM and MeOH (2 x 50 mL). The
48
49
50 combined filtrates and washes were concentrated under reduced pressure. The resulting
51
52
53
54 oil was partitioned between EtOAc (300 mL) and water (100 mL). The organic layer was
55
56
57
58
59
60

1
2
3 washed with brine, dried with Na₂SO₄, and concentrated under reduced pressure to give
4
5
6
7 the crude product as a tan oil. The oil was purified by silica gel column chromatography
8
9
10 to give tert-butyl 5-amino-2-(4-(4-(chloromethyl)benzyloxy)-1-oxoisindolin-2-yl)-5-
11
12
13 oxopentanoate as a white foam. (3.6 g, 87% yield). ¹H NMR (DMSO-*d*₆) δ 7.40 – 7.58 (m,
14
15
16 5H), 7.32 (d, *J* = 2.6 Hz, 1H), 7.29 (d, *J* = 2.3 Hz, 1H), 7.18 – 7.28 (m, 1H), 6.66 – 6.83
17
18 (m, 1H), 5.27 (s, 2H), 4.78 (s, 2H), 4.70 (dd, *J* = 4.7, 10.4 Hz, 1H), 4.43 (s, 2H), 2.14 –
19
20
21 2.35 (m, 1H), 2.00 – 2.14 (m, 3H), 1.39 (s, 9H); ¹³C NMR (DMSO-*d*₆) δ 24.69, 27.56,
22
23
24
25 31.50, 44.78, 45.83, 54.08, 69.13, 81.41, 114.91, 115.26, 127.92, 129.00, 129.73, 130.03,
26
27
28 133.31, 136.78, 137.38, 153.35, 168.09, 169.85, 172.93.
29
30
31
32
33
34
35

36 *Step B.* To a solution of tert-butyl 5-amino-2-(4-(4-(chloromethyl) benzyloxy)-1-
37
38
39 oxoisindolin-2-yl)-5-oxopentanoate (450 mg, 0.95 mmol) and DIEA (0.42 mL, 2.38
40
41
42 mmol) in ACN (9 mL), was added 4-(trifluoromethyl) piperidine hydrochloride (271 mg,
43
44
45 1.43 mmol). The mixture was stirred for 5 h at 60 °C. The crude mixture was partitioned
46
47
48
49 between EtOAc (150 mL) and 1N NaHCO₃ (30 mL). The basic aqueous layer was washed
50
51
52
53 with additional EtOAc (100 mL). The organic layers were combined, washed with brine,
54
55
56
57
58
59
60

1
2
3
4 dried with Na₂SO₄, and concentrated under reduced pressure to give tert-butyl 5-amino-
5
6
7 5-oxo-2-(1-oxo-4-(4-((4-(trifluoromethyl)piperidin-1-yl)methyl)benzyloxy)isoindolin-2-
8
9
10 yl)pentanoate as an oil (570 mg). MS (ESI) *m/z* 590 [M+1]⁺
11
12
13

14
15 *Step C.* To a cooled solution of tert-butyl 5-amino-5-oxo-2-(1-oxo-4-(4-((4-
16
17 (trifluoromethyl)piperidin-1-yl)methyl)benzyloxy)isoindolin-2-yl)pentanoate (561 mg, 0.95
18
19 mmol) in THF (10 mL) in an ice bath, was added t-BuOK (128 mg, 1.14 mmol) as a solid
20
21
22 in one portion. The ice bath was removed and the reaction mixture was stirred for 2 h at
23
24
25 RT. More t-BuOK (28 mg) was added and the reaction mixture was stirred for 2 h. The
26
27
28 reaction mixture was cooled in an ice bath and the reaction quenched with acetic acid
29
30
31 (0.163 mL, 2.85 mmol). The mixture was concentrated under reduced pressure and the
32
33
34 resulting solid was partitioned between EtOAc (100 mL) and 1N NaHCO₃ (30 mL). The
35
36
37 aqueous layer was extracted with EtOAc (50 mL), and the combined organic layer was
38
39
40 washed with brine, dried with Na₂SO₄, and concentrated under reduced pressure to give
41
42
43 a white solid. The solid was triturated with diethyl ether (40 mL), collected by filtration,
44
45
46
47
48
49
50 and washed with additional diethyl ether. The solid was dried and a second trituration was
51
52
53
54
55
56
57
58
59
60

1
2
3 carried out using water (120 mL). The remaining solid was collected and dried to give **24**
4
5
6 as a white solid (328 mg, 67% yield, HPLC >96%). ¹H NMR (DMSO-*d*₆) δ 10.97 (s, 1H),
7
8
9
10 7.39 – 7.55 (m, 3H), 7.21 – 7.39 (m, 4H), 5.17 – 5.28 (m, 2H), 5.11 (dd, *J* = 5.0, 13.3 Hz,
11
12
13 1H), 4.42 (d, *J* = 17.4 Hz, 1H), 4.25 (d, *J* = 17.6 Hz, 1H), 3.48 (s, 2H), 2.78 – 3.00 (m, 3H),
14
15
16
17 2.52 – 2.65 (m, 1H), 2.35 – 2.48 (m, 1H), 2.14 – 2.35 (m, 1H), 1.87 – 2.05 (m, 3H), 1.66 –
18
19
20
21 1.82 (m, 2H), 1.34 – 1.55 (m, 2H); ¹³C NMR (DMSO-*d*₆) δ 22.33, 24.19, 31.18, 38.35,
22
23
24 39.07, 45.06, 51.39, 51.55, 61.59, 69.39, 114.96, 115.20, 127.64, 127.82 (q, *J* = 278 Hz),
25
26
27
28 128.79, 129.80, 129.93, 133.30, 135.22, 138.11, 153.49, 167.99, 170.96, 172.81; MS
29
30
31 (ESI) *m/z* 516 [M+1]⁺; Anal Calcd for C₂₇H₂₈F₃N₃O₄+0.35 H₂O: C, 62.15; H, 5.54; N, 8.05;
32
33
34
35 F, 10.92. Found: C, 62.13; H, 5.48; N, 8.06; F, 9.84; mp: 178-180°C.
36
37
38

39
40 **3-(4-((4,4-Dimethylpiperidin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-**
41
42
43 **2,6-dione (25).** *Step A.* To a stirred solution of **12b** (0.55 g, 1.28 mmol) in ACN (15 mL)
44
45
46 at RT, were added 4,4-dimethylpiperidine hydrochloride (0.23 g, 1.53 mmol) and DIEA
47
48
49 (0.46 mL, 2.81 mmol). The mixture was stirred overnight and then concentrated to give
50
51
52
53 an oil, which was purified by silica gel column chromatography to give methyl 5-amino-4-
54
55
56
57
58
59
60

1
2
3
4 (4-(4-((4,4-dimethylpiperidin-1-yl)methyl)benzyloxy)-1-oxoisindolin-2-yl)-5-
5
6
7 oxopentanoate as a light yellow solid (0.60 g, 92% yield).
8
9

10
11 *Step B.* To a stirred solution of methyl 5-amino-4-(4-(4-((4,4-dimethylpiperidin-1-
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2

1
2
3
4 167.98, 170.97, 172.82; MS (ESI) m/z 476 $[M+1]^+$; Anal. Calcd for $C_{28}H_{33}N_3O_4$: C, 70.71;
5
6
7 H, 6.99; N, 8.84. Found: C, 66.15; H, 6.50; N, 8.02; mp: 168-170°C.
8
9

10
11 **3-(4-((4-((4,4-Difluoropiperidin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-**
12
13
14
15 **2,6-dione (26).** *Step A.* To a stirred solution of **12b** (500 mg, 1.160 mmol) and 4,4-
16
17
18 difluoropiperidine hydrochloride (274 mg, 1.741 mmol) in ACN (10 mL) under a nitrogen
19
20
21 atmosphere, were added Na_2CO_3 (160 mg, 1.160 mmol) and DIEA (0.507 mL, 2.90
22
23
24 mmol). The resulting solution was stirred at 50 °C for 8 h. The reaction mixture was diluted
25
26
27 by DCM (50 mL) and extracted with brine (20 mL). The organic layer was dried with
28
29
30
31
32 $MgSO_4$ and concentrated under vacuum to give methyl 5-amino-4-(4-((4-((4,4-
33
34
35 difluoropiperidin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)-5-oxopentanoate as an off
36
37
38
39 white solid (630 mg, 105% crude yield). MS (ESI) m/z 516 $[M+1]^+$.
40
41
42
43

44 *Step B.* To a stirred solution of methyl 5-amino-4-(4-((4-((4,4-difluoropiperidin-1-
45
46
47 yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)-5-oxopentanoate (630 mg, 1.222 mmol) in
48
49
50 THF (10 mL) at 0 °C was added t-BuOK (151 mg, 1.344 mmol). The mixture was stirred
51
52
53
54 at 0 °C for 5 min. The reaction mixture was diluted with DCM (50 mL) and acidified by
55
56
57
58
59
60

1
2
3
4 HCl (1N, aq. 3 mL) to pH=2. The mixture was extracted with a mixture of NaHCO₃ (aq.
5
6
7 sat., 5 mL) and brine (10 mL). The organic layer was dried over MgSO₄ and concentrated.
8
9
10 The residue was stirred in ether (50 mL) and the product was collected by vacuum
11
12
13 filtration to give a white solid. The solid was triturated in EtOAc (5 mL) and collected by
14
15
16 filtration to give **26** as a white solid (215 mg, 36% yield, HPLC purity >99%). ¹H NMR
17
18 (DMSO-*d*₆) δ 10.97 (s, 1H), 7.40 – 7.54 (m, 3H), 7.33 (d, 4H), 5.23 (s, 2H,), 5.11 (dd, *J*=
19
20
21 5.1, 13.2 Hz, 1H), 4.42 (d, *J*= 17.6 Hz, 1H), 4.25 (d, *J*= 17.6 Hz, 1H), 3.55 (s, 2H), 2.81
22
23
24 – 3.02 (m, 1H), 2.54 – 2.64 (m, 1H), 2.34 – 2.49 (m, 5H), 1.84 – 2.09 (m, 5H); ¹³C NMR
25
26
27 (DMSO-*d*₆) δ 22.29, 31.12, 33.25 (t, *J*_{C-F} = 20.9 Hz), 45.00, 49.12, 51.51, 60.40, 69.29,
28
29
30
31 114.89, 115.16, 122.68 (t, *J*_{C-F} = 239.9 Hz), 127.60, 128.84, 129.73, 129.88, 133.24,
32
33
34
35 135.32, 137.72, 153.42, 167.93, 170.91, 172.76; Anal. Calcd for C₂₆H₂₇F₂N₃O₅+1 H₂O:
36
37
38 C, 62.27; H, 5.83; N, 8.39, Found: C, 62.09; H, 5.73; N, 8.17; MS (ESI) *m/z* 484 [M+1]⁺;
39
40
41
42
43
44
45 mp 193 – 195°C.
46
47
48
49

50 **3-(4-((4-((4-Methylpiperidin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-**
51
52
53 **dione (27)**. 4-Methylpiperidine (0.49 g, 4.94 mmol) was added to a stirred solution of **12b**
54
55
56
57
58
59
60

1
2
3
4 (0.71 g, 1.65 mmol) in DMF (15 mL) at 50°C overnight. To the mixture was added K₂CO₃
5
6
7 (0.23 g, 1.65 mmol), and the mixture was heated to 90 °C overnight. The mixture was
8
9
10 concentrated to give an oil, which was stirred in EtOAc (10 mL) overnight. The suspension
11
12
13 was filtered to give a brown filtrate, which was concentrated under reduced pressure. The
14
15
16 residue was purified by silica gel column chromatography to give **27** as a white solid (0.22
17
18 g, 29% yield, HPLC purity >98%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.98 (s, 1H), 10.69
19
20
21 (br. s., 1H), 7.70 – 7.62 (m, 2H), 7.59 – 7.54 (m, 2H), 7.52 – 7.46 (m, 1H), 7.36 – 7.31 (m,
22
23
24 2H), 5.28 (s, 2H), 5.12 (dd, *J* = 5.0, 13.3 Hz, 1H), 4.44 (d, *J* = 17.6 Hz, 1H), 4.30 (s, 1H),
25
26
27 4.27 – 4.20 (m, 2H), 3.27 – 3.23 (m, 2H), 2.97 – 2.78 (m, 3H), 2.60 – 2.56 (m, 1H), 2.48 –
28
29
30 2.42 (m, 1H), 2.03 – 1.92 (m, 1H), 1.75 – 1.72 (m, 2H), 1.62 – 1.40 (m, 3H), 0.89 (d, *J* =
31
32
33 5.8 Hz, 3H); ¹³C NMR (DMSO-*d*₆) δ 21.79, 22.36, 30.23, 31.21, 33.89, 45.10, 51.58,
34
35
36 53.22, 62.10, 69.44, 114.97, 115.23, 127.61, 128.86, 129.81, 129.94, 133.31, 135.12,
37
38
39 153.51, 168.01, 170.96, 172.83; MS (ESI) *m/z* 462 [M+1]⁺; Anal. Calcd for
40
41
42 C₂₇H₃₁N₃O₄+0.1 H₂O: C, 69.99; H, 6.79; N, 9.07. Found: C, 69.84; H, 6.81; N, 9.12; mp:
43
44
45
46
47
48
49 189-191°C.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **3-(4-((4-((2,4-Dichlorophenyl)-2-oxopiperazin-1-yl)methyl)benzyl)oxy)-1-**

5
6
7 **oxoisindolin-2-yl)piperidine-2,6-dione (28).** 4-(2,4-Dichlorophenyl)piperazin-2-one (124

8
9
10 mg, 0.506 mmol) was dissolved into dry DMF (1.5 mL) and cooled to 0 °C. Sodium hydride

11
12
13 (60% dispersion in mineral oil, 25 mg, 0.625 mmol) was added in one portion, and the

14
15
16 solution was stirred for 5 min. 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisindolin-2-

17
18
19 yl)piperidine-2,6-dione (112 mg, 0.253 mmol) was then added as a solid in one portion.

20
21
22 After 20 min, another portion of sodium hydride (60% dispersion in mineral oil, 34 mg,

23
24
25 0.850 mmol) was added. After 20 min, another portion of 3-(4-((4-

26
27
28 (bromomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (86.8 mg, 0.196

29
30
31 mmol) was added, with the reaction now at RT. After 5 h, the reaction was added to 1N

32
33
34 HCl and poured in a separatory funnel, then diluted with DCM and THF. The organic layer

35
36
37 was removed, and the aqueous layer extracted with a mixture of DCM and THF to

38
39
40 solubilize some of the solid. The combined organic solution was dried over MgSO₄,

41
42
43 filtered, and concentrated. The crude product was purified by HPLC to give **28**. (15.5 mg,

44
45
46 0.026 mmol, 5.0% yield, HPLC purity >98%).¹H NMR (500 MHz, DMSO-*d*₆) δ 10.96 (s,

47
48
49 1H), 7.59 (d, *J* = 2.52 Hz, 1H), 7.46 – 7.53 (m, 3H), 7.37 – 7.42 (m, 1H), 7.33 (s, 5H), 7.15

1
2
3
4 – 7.22 (m, 1H), 5.25 (s, 2H), 5.11 (dd, $J = 13.24, 5.36$ Hz, 1H), 4.60 (s, 2H), 4.43 (d, $J =$
5
6
7 17.34 Hz, 1H), 4.27 (d, $J = 17.65$ Hz, 1H), 3.74 (s, 2H), 2.82 – 3.01 (m, 1H), 2.54 – 2.67
8
9
10 (m, 2H), 2.34 – 2.45 (m, 2H), 1.90 – 2.03 (m, 1H); MS (ESI): m/z 607.2 $[M+1]^+$.

11
12
13
14 **3-(4-((4-((4-(5-Fluoropyridin-2-yl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**
15
16
17 **yl)piperidine-2,6-dione (29).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisindolin-2-
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
purified by HPLC to give **29**. (0.131 mg, 0.241 mmol, 90% yield, HPLC purity >96%). ^1H
NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.03 (br. s., 1H), 10.97 (s, 1H), 8.12 (d, $J = 3.12$ Hz, 1H),
7.52 – 7.65 (m, 5H), 7.47 (t, $J = 7.81$ Hz, 1H), 7.24 – 7.35 (m, 2H), 6.95 (dd, $J = 9.37, 3.51$
Hz, 1H), 5.27 (s, 2H), 5.10 (dd, $J = 13.28, 5.08$ Hz, 1H), 4.42 (d, $J = 17.18$ Hz, 1H), 4.34
(d, $J = 5.08$ Hz, 2H), 4.19 – 4.30 (m, 3H), 3.74 (quin, $J = 6.05$ Hz, 1H), 3.32 (d, $J = 11.72$
Hz, 2H), 3.15 – 3.28 (m, 2H), 2.97 – 3.10 (m, 2H), 2.81 – 2.95 (m, 1H), 2.50 – 2.60 (m,
1H), 2.42 (dd, $J = 13.08, 4.49$ Hz, 1H), 1.90 – 2.02 (m, 1H); MS (ESI) m/z 544.5 $[M+1]^+$.

1
2
3
4 **3-(1-Oxo-4-((4-((4-(pyridin-2-yl)piperazin-1-yl)methyl)benzyl)oxy)isoindolin-2-**
5
6
7 **yl)piperidine-2,6-dione, HCl (30).** 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisoindolin-2-
8
9
10 yl)piperidine-2,6-dione (0.050 g, 0.113 mmol) was placed in a vial with 1-(pyridin-2-
11
12 yl)piperazine.2HCl (0.029 g, 0.124 mmol), DIEA (0.059 mL, 0.338 mmol), and ACN (1.0
13
14 mL). The reaction mixture was stirred at 40 °C for 18 h. The reaction mixture was taken
15
16
17
18
19
20
21 up in DMSO (1.0 mL) and purified by HPLC. Fractions containing the desired product
22
23
24
25 were combined and volatile organics were removed under reduced pressure to give a
26
27
28 white solid. The solid was taken up in methanol and three drops of 6N HCl solution were
29
30
31 added. Volatile organics were removed under reduced pressure to give **30** (0.038 g, 0.068
32
33
34 mmol, 59.9% yield, HPLC purity >97%) as a white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ
35
36
37 10.96 (s, 1H), 8.12 – 8.15 (m, 1H), 7.81 (t, *J* = 7.41 Hz, 1H), 7.65 – 7.69 (m, 2H), 7.59 (d,
38
39 *J* = 8.20 Hz, 2H), 7.47 – 7.52 (m, 1H), 7.32 – 7.36 (m, 2H), 7.12 (d, *J* = 6.94 Hz, 1H), 6.87
40
41
42 (t, *J* = 5.99 Hz, 1H), 5.30 (s, 2H), 5.12 (dd, *J* = 5.20, 13.40 Hz, 1H), 4.34 – 4.48 (m, 5H),
43
44
45
46
47
48 4.29 (d, *J* = 17.65 Hz, 1H), 3.43 – 3.53 (m, 2H), 3.38 (d, *J* = 12.61 Hz, 2H), 3.12 (d, *J* =
49
50
51
52 8.51 Hz, 2H), 2.91 (ddd, *J* = 5.36, 13.71, 17.50 Hz, 1H), 2.55 – 2.62 (m, 1H), 2.40 – 2.48
53
54
55
56 (m, 1H), 1.99 (dtd, *J* = 1.58, 5.12, 12.45 Hz, 1H); MS (ESI) *m/z* 526.2 [M+1]⁺.
57
58
59
60

1
2
3 **5-(4-(4-(((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-**
4
5
6
7 **yl)picolinamide (31).** 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-
8
9
10 2,6-dione (0.100 g, 0.226 mmol) was placed in a vial with 5-(piperazin-1-yl)picolinamide
11
12 (0.047 g, 0.226 mmol), DMF (1.0 mL), and DIEA (0.078 mL, 0.445 mmol). The reaction
13
14 mixture was stirred at 40 °C for 18 h. DMSO (1 mL) was added to the vial and the crude
15
16
17 material was purified by HPLC. Fractions containing the desired product were combined
18
19
20 and volatile organics were removed under reduced pressure to give **31** (0.058 g, 0.102
21
22
23 mmol, 45.2% yield, HPLC purity >99%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ
24
25 10.97 (s, 1H), 8.26 (d, *J* = 2.69 Hz, 1H), 7.84 (d, *J* = 8.80 Hz, 1H), 7.77 (br d, *J* = 2.20 Hz,
26
27 1H), 7.44 – 7.53 (m, 3H), 7.27 – 7.41 (m, 6H), 5.25 (s, 2H), 5.12 (dd, *J* = 5.01, 13.33 Hz,
28
29 1H), 4.38 – 4.49 (m, 1H), 4.21 – 4.32 (m, 1H), 3.55 (s, 2H), 2.81 – 3.02 (m, 1H), 2.60 (br
30
31 s, 1H), 2.37 – 2.48 (m, 1H), 1.89 – 2.07 (m, 1H); MS (ESI) *m/z* 569.2 [M+1]⁺.
32
33
34
35
36
37
38
39
40
41
42
43

44
45 **2-(4-(4-(((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-**
46
47
48 **yl)nicotinonitrile, HCl (32).** To 3-(4-((4-(bromomethyl)benzyl)oxy)-1-oxoisoindolin-2-
49
50
51
52
53
54
55
56
57
58
59
60 0.805 mmol) followed by 2-(piperazin-1-yl)nicotinonitrile (0.061 g, 0.322 mmol). The

1
2
3
4 reaction was stirred overnight at RT, then the mixture was concentrated and purified by
5
6
7 HPLC. Fractions containing the desired product were combined and 4 drops of 6 M HCl
8
9
10 were added. The solution was frozen and lyophilized to give **32**. (0.037 g, 0.067 mmol,
11
12
13 25% yield, HPLC purity >99%). ¹H NMR (400MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 10.78 (br.
14
15
16 s., 1H), 8.49 (dd, *J* = 4.9, 1.8 Hz, 1H), 8.19 (dd, *J* = 7.6, 1.8 Hz, 1H), 7.58 – 7.66 (m, 4H),
17
18
19
20
21 7.50 (t, *J* = 7.8 Hz, 1H), 7.31 – 7.38 (m, 2H), 7.09 (dd, *J* = 7.4, 4.7 Hz, 1H), 5.31 (s, 2H),
22
23
24 5.13 (dd, *J* = 13.3, 5.1 Hz, 1H), 4.38 – 4.48 (m, 3H), 4.21 – 4.33 (m, 3H), 3.40 – 3.50 (m,
25
26
27 4H), 3.20 (d, *J* = 11.7 Hz, 2H), 2.87 – 2.98 (m, 1H), 2.56 – 2.64 (m, 1H), 2.38 – 2.48 (m,
28
29
30
31 1H), 1.96 – 2.03 ppm (m, 1H); MS (ESI) *m/z* 551.5 [M+1]⁺.

32
33
34
35 **4-(4-(4-(((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-**
36
37
38 **yl)-3-fluorobenzonitrile (33).** 3-(4-((4-(Bromomethyl)benzyl)oxy)-1-oxoisoindolin-2-
39
40
41 yl)piperidine-2,6-dione (0.200 g, 0.451 mmol) was placed in a vial with 3-fluoro-4-
42
43
44 (piperazin-1-yl)benzonitrile (0.102 g, 0.496 mmol), DIEA (0.236 mL, 1.354 mmol), and
45
46
47
48 ACN (4.0 mL). The reaction mixture was stirred at 40 °C for 18 h. The reaction mixture
49
50
51
52 was taken up in DMSO (4.0 mL) and purified by HPLC to give **33** (0.170 g, 0.300 mmol,
53
54
55 66.4% yield, HPLC purity >99%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.97
56
57
58
59
60

1
2
3 (s, 1H), 7.69 (dd, $J = 1.96, 13.45$ Hz, 1H), 7.57 (dd, $J = 1.71, 8.56$ Hz, 1H), 7.44 – 7.52
4
5
6
7 (m, 3H), 7.30 – 7.40 (m, 4H), 7.12 (t, $J = 8.68$ Hz, 1H), 5.24 (s, 2H), 5.12 (dd, $J = 5.14,$
8
9
10 13.20 Hz, 1H), 4.38 – 4.48 (m, 1H), 4.22 – 4.31 (m, 1H), 3.55 (s, 2H), 3.14 – 3.23 (m, 4H),
11
12
13 2.85 – 2.98 (m, 1H), 2.53 (br d, $J = 4.65$ Hz, 5H), 2.39 – 2.48 (m, 1H), 1.93 – 2.05 (m, 1H);
14
15
16

17 MS (ESI) m/z 568.2 $[M+1]^+$.
18
19
20
21

22 **3-(4-((4-((4-Methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-**
23
24
25 **dione (34).** *Step A.* Polymer-supported triphenylphosphine (1.6 mmol/g, 1.36 g, 1.85
26
27 mmol) was added to a stirred solution of **11** (0.45 g, 1.54 mmol) in THF (20 mL) at 0 °C
28
29 followed by addition of DIAD (0.37 mL, 1.88 mmol). After stirring for 30 min, [4-(4-methyl-
30
31 piperazin-1-ylmethyl)-phenyl]methanol (0.41 g, 1.85 mmol) was added. The mixture was
32
33 stirred for 3 h then filtered, washed with methanol (3 x 10 mL) and DCM (3 x 10 mL). The
34
35 combined filtrate was evaporated in vacuo to give an oil, which was purified by silica gel
36
37 column chromatography to give methyl 5-amino-4-(4-((4-((4-methylpiperazin-1-
38
39 yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)-5-oxopentanoate as a clear oil (0.50 g, 66%
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 yield).

1
2
3
4 *Step B.* Potassium tert-butoxide (0.11 g, 1.01 mmol) was added to a stirred solution of
5
6
7 methyl 5-amino-4-(4-((4-methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-
8
9
10 yl)-5-oxopentanoate (0.50 g, 1.01 mmol) in THF (15 mL) at 0 °C. The mixture was stirred
11
12
13 for 10 min and the reaction was quenched with 1N HCl (3 mL), the pH was neutralized by
14
15
16 saturated sodium bicarbonate (4 mL to pH=7), and the crude product quickly extracted
17
18
19 with EtOAc (2 x 30 mL). The combined organic phases were evaporated to give an off-
20
21
22 white solid, which was stirred in EtOAc (10 mL) for 1 h. The suspension was filtered and
23
24
25 dried to give **34** as an off-white solid (0.12 g, 26% yield, HPLC purity >99%). ¹H NMR
26
27
28 (DMSO-*d*₆) δ 10.97 (s, 1H), 7.23 – 7.56 (m, 7H), 5.22 (s, 2H), 5.11 (dd, *J* = 5.2, 13.1 Hz,
29
30
31 1H), 4.17 – 4.50 (m, 2H), 3.45 (s, 2H), 2.80 – 3.05 (m, 1H), 2.55 – 2.66 (m, 1H), 2.20 –
32
33
34 2.46 (m, 9H), 2.14 (s, 3H), 1.90 – 2.04 (m, 1H); ¹³C NMR (DMSO-*d*₆) δ 22.36, 31.21,
35
36
37 45.09, 45.72, 51.58, 52.52, 54.71, 61.74, 69.44, 114.98, 115.23, 127.62, 128.88, 129.81,
38
39
40 129.95, 133.31, 135.17, 138.18, 153.51, 168.01, 170.96, 172.82; MS (ESI) *m/z* 463
41
42
43
44
45
46
47
48 [M+1]⁺; Anal. Calcd for C₂₆H₃₀N₄O₄ : C, 67.51; H, 6.54; N, 12.11; Found: C, 67.23; H,
49
50
51 6.67; N, 11.78; mp 188-190 °C.
52
53
54
55
56
57
58
59
60

1
2
3
4 **[4-(Bromomethyl)phenyl]methoxy-tert-butyl-dimethyl-silane (36)**. *Step A*. To a solution of
5
6
7 methyl 4-(hydroxymethyl)benzoate (**35**) (20.0 g, 120.36 mmol) and imidazole (12.29 g,
8
9
10 180.54 mmol) in DMF (250.00 mL) was added TBSCl (27.21 g, 180.54 mmol, 22.12 mL)
11
12
13 at 0 °C. The mixture was stirred at 25°C for 16 h. The reaction was quenched with water
14
15
16 (300 mL) and extracted with EtOAc (3 x 200 mL). The combined organic phase was
17
18
19 washed with brine (3 x 300 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated
20
21
22 under reduced pressure. The residue was purified by column chromatography to give
23
24
25 crude methyl 4-[[tert-butyl(dimethyl)silyl]oxymethyl]benzoate (36.00 g) as a white solid.¹H
26
27
28 NMR (CDCl₃, 400 MHz) δ 8.01 (d, *J* = 8.0 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 2H), 4.80 (s, 2H),
29
30
31 3.92 (s, 3H), 0.96 (s, 9H), 0.11 (s, 6H).
32
33
34
35
36
37
38

39 *Step B*. To a mixture of LiAlH₄ (7.31 g, 192.56 mmol) in THF (800.0 mL) was added methyl
40
41
42 4-[[tert-butyl(dimethyl)silyl]oxymethyl]benzoate (36.0 g, 128.37 mmol) in THF (800 mL) in
43
44
45 one portion at 0 °C under nitrogen. The mixture was stirred at 0 °C for 1 h, then was
46
47
48 quenched with water followed by aqueous 20% NaOH. The mixture was filtered and the
49
50
51 filtrate was concentrated under reduced pressure. The residue was purified by silica gel
52
53
54
55
56
57
58
59
60

1
2
3
4 column chromatography to give [4-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]methanol
5
6
7 (26.00 g, 103.00 mmol, 80.2% yield) as a white solid. ^1H NMR (CDCl_3 , 400 MHz) δ 7.37
8
9
10 – 7.32 (m, 4H), 4.76 (s, 2H), 4.70 (s, 2H), 0.97 (s, 9H), 0.12 (s, 6H).
11
12
13

14 *Step C.* To a solution of NBS (8.46 g, 47.54 mmol) in DCM (75.0 mL) at 0 °C was added
15
16 Me_2S (3.94 g, 63.39 mmol, 4.63 mL). The bright yellow mixture was stirred at 0 °C for 15
17
18 min then cooled to -20°C. At this temperature, a pre-cooled solution of [4-[[tert-
19
20 butyl(dimethyl)silyl]oxymethyl]phenyl]methanol (8.00 g, 31.69 mmol) in DCM (25 mL) was
21
22 added via syringe. The resulting mixture was warmed to 0 °C and stirred for 15 min, then
23
24 warmed at 25 °C for 2 h. The mixture was poured into ice-water (50 mL) and stirred for
25
26 10 min. The aqueous phase was extracted with DCM (3 x 30 mL). The combined organic
27
28 phase was washed with brine (2 x 15 mL), dried with anhydrous Na_2SO_4 , filtered, and
29
30 concentrated under reduced pressure. The residue was added to water (30 mL) and
31
32 extracted with n-hexane (2 x 30 mL). The organic layer was dried with anhydrous Na_2SO_4 ,
33
34 filtered, and concentrated under reduced pressure to give crude **36** (8.00 g). The crude
35
36 material was used in the next step without further purification.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Methyl 5-amino-4-[4-[[4-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]methoxy]-1-oxo-**
4
5
6 **isoindolin-2-yl]-5-oxo-pentanoate (37).** To a mixture of [4-(bromomethyl)phenyl]methoxy-
7
8
9
10 tert-butyl-dimethyl-silane (10.0 g, 31.71 mmol) and methyl 5-amino-4-(4-hydroxy-1-oxo-
11
12
13 isoindolin-2-yl)-5-oxo-pentanoate (11.12 g, 38.05 mmol) in DMF (100 mL) was added
14
15
16
17 K_2CO_3 (26.30 g, 190.26 mmol) in one portion at 25 °C under nitrogen. The mixture was
18
19
20
21 stirred at 25 °C for 16 h. The reaction mixture was poured into ice-water (100 mL) and
22
23
24 extracted with EtOAc (3 x 50 mL). The combined organic phase was washed with brine
25
26
27
28 (5 x 50 mL), dried with anhydrous Na_2SO_4 , filtered, and concentrated under reduced
29
30
31 pressure. The residue was washed with petroleum ether and EtOAc (1:1, 50 mL) to give
32
33
34 **37** (7.50 g, 14.24 mmol, 44.9% yield) as a white solid. MS (ESI) m/z 549.2 $[M+23]^+$.
35
36
37
38

39 **3-[4-[[4-(Hydroxymethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]-1-methyl-piperidine-2,6-**
40
41
42 **dione (38).** *Step A.* To a mixture of potassium *tert*-butoxide (2.40 g, 21.36 mmol) in THF
43
44
45 (50 mL) was added **37** (7.50 g, 14.24 mmol) in THF (50 mL) in one portion at 0 °C under
46
47
48
49 nitrogen. The mixture was stirred at 0 °C for 2 h. The reaction mixture was poured into
50
51
52
53 aqueous HCl (1 mol/L) (200 mL). The aqueous phase was extracted with EtOAc (3 x 50
54
55
56
57
58
59
60

1
2
3 mL). The combined organic phase was washed with brine (2 x 50 mL) and concentrated
4
5
6
7 under reduced pressure to give 3-[4-[[4-[[tert-
8
9
10 butyl(dimethyl)silyl]oxymethyl]phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione
11
12
13 (6.50 g, crude) as white solid. MS (ESI) m/z 495.2 [M+1]⁺.
14
15
16
17

18 *Step B.* To a mixture of 3-[4-[[4-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]methoxy]-1-
19
20
21 oxo-isoindolin-2-yl]piperidine-2,6-dione (6.50 g, 13.14 mmol) in THF (100 mL) was added
22
23
24 H₂SO₄ (3 M, 30.0 mL) in one portion at 20 °C under nitrogen. The mixture was stirred at
25
26
27
28 20 °C for 2 h. The pH of the reaction mixture was adjusted with saturated aqueous sodium
29
30
31 bicarbonate to pH = 6, then the product was extracted with EtOAc (2 x 50 mL). The
32
33
34 combined organic phase was washed with brine (2 x 100 mL), dried over Na₂SO₄, and
35
36
37 concentrated. The residue was triturated with petroleum ether:EtOAc (10:1, 50 mL) to
38
39
40 give 3-[4-[[4-(hydroxymethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione
41
42
43 (4.20 g, 11.04 mmol, 84.0% yield) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.90
44
45
46
47
48
49 (s, 1H), 7.45 – 7.33 (m, 3H), 7.25 – 7.22 (m, 4H), 5.15 (s, 2H), 5.03 (dd, *J* = 5.0, 13.2 Hz,
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1H), 4.42 (s, 2H), 4.33 (d, $J = 17.6$ Hz, 1H), 4.18 (d, $J = 17.6$ Hz, 1H), 2.93 – 2.75 (m, 1H),
5
6
7 2.53 – 2.51 (m, 1H), 2.39 – 2.30 (m, 1H), 1.95 – 1.85 (m, 1H); MS (ESI) m/z 381.2 $[M+1]^+$.
8
9

10
11 *Step C.* To a mixture of 3-[4-[[4-(hydroxymethyl)phenyl]methoxy]-1-oxo-isindolin-2-
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
yl]piperidine-2,6-dione (400 mg, 1.05 mmol) and K_2CO_3 (436 mg, 3.15 mmol) in DMF
(5.00 mL) was added methyl iodide (447 mg, 3.15 mmol) in one portion at 0 °C under
nitrogen, then heated to 15 °C and stirred for 5 h. The mixture was poured into HCl (1N,
10 mL). The aqueous phase was extracted with EtOAc (3 x 30 mL). The combined
organic phase was washed with brine (3 x 30 mL), dried with anhydrous Na_2SO_4 , filtered
and concentrated under vacuum. The residue was purified by silica gel column
chromatography to give **38** (300 mg, 0.761 mmol, 72.4% yield) as a white solid. 1H NMR
(400 MHz, $DMSO-d_6$) δ 7.53 – 7.41 (m, 3H), 7.37 – 7.28 (m, 4H), 5.23 (s, 2H), 5.20 – 5.15
(m, 1H), 4.50 (d, $J = 5.8$ Hz, 2H), 4.40 (d, $J = 17.6$ Hz, 1H), 4.25 (d, $J = 17.6$ Hz, 1H), 3.00
(s, 3H), 2.79 – 2.69 (m, 1H), 2.56 – 2.52 (m, 1H), 2.46 – 2.42 (m, 1H), 2.03 – 1.97 (m, 1H);
MS (ESI) m/z 395.2 $[M+1]^+$.

1
2
3
4 **3-[4-[[4-[[4-(2,4-Difluorophenyl)piperazin-1-yl]methyl]phenyl]methoxy]-1-oxo-isindolin-**
5
6
7 **2-yl]-1-methyl-piperidine-2,6-dione (39).** *Step A.* To a mixture of **38** (300 mg, 0.761 mmol)
8
9
10 and DIEA (245 mg, 1.90 mmol) in DMF (10.0 mL) was added methanesulfonyl chloride
11
12
13 (104 mg, 0.913 mmol) in one portion at -5 °C under nitrogen. The mixture was stirred at
14
15
16
17 -5 °C for 1 h. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined
18
19
20
21 organic phase was washed with brine (2 x 20 mL), dried with anhydrous Na₂SO₄, filtered,
22
23
24 and concentrated under vacuum to give crude [4-[[2-(1-methyl-2,6-dioxo-3-piperidyl)-1-
25
26
27
28 oxo-isindolin-4-yl]oxymethyl]phenyl]methylmethanesulfonate (360 mg) as a colorless
29
30
31 oil. The residue was used in the next step without further purification. MS (ESI) *m/z* 473.2
32
33
34
35 [M+1]⁺.
36
37
38

39 *Step B.* To a mixture of [4-[[2-(1-methyl-2,6-dioxo-3-piperidyl)-1-oxo-isindolin-4-
40
41
42 yl]oxymethyl]phenyl]methyl methanesulfonate (360 mg, 0.762 mmol) and 1-(2,4-
43
44
45 difluorophenyl)piperazine (226 mg, 1.14 mmol) in DMF (5.0 mL) was added DIEA (385
46
47
48 mg, 3.81 mmol) in one portion at 25 °C under nitrogen. The mixture was stirred at 25 °C
49
50
51
52 for 16 h. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined
53
54
55
56
57
58
59
60

1
2
3 organic phase was washed with brine (2 x 30 mL), dried with anhydrous Na₂SO₄, filtered,
4
5
6
7 and concentrated in vacuum. The residue was purified by HPLC to give **39** (110 mg, 0.191
8
9
10 mmol, 25.1% yield, HPLC purity >99%) as white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ
11
12
13 11.89 (br. s., 1H), 7.75 (d, *J* = 8.0 Hz, 2H), 7.59 (d, *J* = 8.0 Hz, 2H), 7.54 – 7.47 (m, 1H),
14
15
16
17 7.41 – 7.32 (m, 2H), 7.26 – 7.21 (m, 1H), 7.15 – 7.10 (m, 1H), 7.05 – 7.00 (m, 1H), 5.29
18
19
20
21 (s, 1H), 5.20 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.44 (d, *J* = 17.6 Hz, 1H), 4.39 (d, *J* = 4.8 Hz, 2H),
22
23
24
25 4.38 (d, *J* = 17.6 Hz, 1H), 3.47 – 3.13 (m, 8H), 3.07 – 2.90 (m, 4H), 2.79 – 2.70 (m, 1H),
26
27
28 2.49 – 2.37 (m, 1H), 2.07 – 1.93 (m, 1H); MS (ESI) *m/z* 575.3 [M+1]⁺.
29
30
31

32 **3-(4-(Benzyloxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (40).** 3-(4-Hydroxy-1-
33
34
35 oxoisindolin-2-yl)piperidine-2,6-dione (0.150 g, 0.576 mmol) was placed in a vial with
36
37
38 acetone (2.5 mL), (bromomethyl)benzene (0.099 g, 0.576 mmol), and potassium
39
40
41 carbonate (0.199 g, 1.441 mmol). The reaction mixture was heated to 45 °C for 18 h. The
42
43
44
45
46 reaction mixture was diluted with DMSO (2 mL) and filtered. Acetone was removed under
47
48
49
50 reduced pressure. The remaining mixture was purified by HPLC to give **40** (0.017 g, 0.049
51
52
53 mmol, 8.4% yield, HPLC purity >99%) as a white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ
54
55
56
57
58
59
60

1
2
3
4 10.96 (s, 1H), 7.46 – 7.53 (m, 3H), 7.41 (t, $J = 7.25$ Hz, 2H), 7.31 – 7.38 (m, 3H), 5.27 (s,
5
6
7 2H), 5.12 (dd, $J = 5.04, 13.24$ Hz, 1H), 4.43 (d, $J = 17.34$ Hz, 1H), 4.28 (d, $J = 17.65$ Hz,
8
9
10 1H), 2.92 (ddd, $J = 5.36, 13.79, 17.42$ Hz, 1H), 2.59 (td, $J = 1.97, 15.29$ Hz, 1H), 2.41 –
11
12
13 2.49 (m, 1H), 1.94 – 2.04 (m, 1H); MS (ESI) m/z 351.2 $[M+1]^+$.
14
15
16
17
18
19
20

21 **2-(2,6-Dioxo-3-piperidyl)-4-hydroxy-isoindoline-1,3-dione (42)**. To a solution of 4-
22
23
24 hydroxyisobenzofuran-1,3-dione (**41**) (5.0 g, 30.47 mmol) in acetic acid (60.0 mL) was
25
26
27 added sodium acetate (5.0 g, 60.94 mmol) and 3-aminopiperidine-2,6-dione HCl (5.02 g,
28
29
30 30.47 mmol). The mixture was stirred at 100 °C for 2 h. The reaction mixture was
31
32
33 concentrated to 20 mL, then poured into ice-water (300 mL). The precipitate was
34
35 concentrated to 20 mL, then poured into ice-water (300 mL). The precipitate was
36
37 collected by filtration, and the filter cake was washed with ice-water (50 mL). The cake
38
39
40 was poured into stirring EtOAc (50 mL) and petroleum ether (50 mL). After 30 min, the
41
42 precipitate was removed by filtration and the filtrate was concentrated to give **42** (6.00 g,
43
44
45 21.88 mmol, 71.81% yield) as a purple solid. ^1H NMR (DMSO- d_6 , 400MHz) δ 11.20 (s,
46
47
48 1H), 11.10 (s, 1H), 7.65 (dd, $J = 8.4, 7.2$ Hz, 1 H), 7.32 (d, $J = 7.2$ Hz, 1H), 7.25 (d, $J =$
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 8.4 Hz, 1H), 5.07 (dd, $J = 12.8, 5.4$ Hz, 1H), 2.93 – 2.84 (m, 1H), 2.61 – 2.53 (m, 2H),
5
6
7 2.04 – 2.00 (m, 1H); MS (ESI) m/z 275.1 [M+1]⁺.
8
9

10
11 **4-[[4-[[tert-Butyl(dimethyl)silyl]oxymethyl]phenyl]methoxy]-2-(2,6-dioxo-3-**

12
13
14 **piperidyl)isoindoline-1,3-dione (43).** To a solution of **42** (2.50 g, 9.12 mmol) in DMF (30.0
15
16 mL) was added K₂CO₃ (2.52 g, 18.24 mmol) and **36** (3.59 g, 9.12 mmol). The mixture was
17
18 stirred at 20 °C for 3 h. The mixture was diluted with water (50 mL) and extracted with
19
20 EtOAc (2 x 30 mL). The combined organic phase was washed with saturated brine (2 x
21
22 35 mL), dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure.
23
24

25
26
27
28
29
30
31
32 The residue was purified by silica gel column chromatography to give **43** (1.80 g, 3.54
33
34 mmol, 38.8% yield) as a white solid. ¹H NMR (CDCl₃, 400 MHz) δ 11.12 (s, 1H), 7.82 (dd,
35
36 $J = 8.4, 7.2$ Hz, 1H), 7.59 (d, $J = 8.4$ Hz, 1H), 7.49 – 7.45 (m, 3H), 7.34 (d, $J = 8.0$ Hz,
37
38 2H), 5.36 (s, 2H), 5.09 (dd, $J = 12.8, 5.4$ Hz, 1H), 4.72 (s, 2H), 2.93 – 2.84 (m, 1H), 2.56
39
40 – 2.53 (m, 1H), 2.45 – 2.49 (m, 1H), 2.07 – 2.01 (m, 1H), 0.90 (s, 9H), 0.08 (s, 6H); MS
41
42
43
44
45
46
47
48
49 (ESI) m/z 377.1 [M-OTBS]⁺.
50
51
52
53
54
55
56
57
58
59
60

[4-[[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-isoindolin-4-

yl]oxymethyl]phenyl]methanesulfonate (44). *Step A.* To a solution of **43** (1.80 g, 3.54 mmol) in THF (30.00 mL) was added H₂SO₄ (0.5 M, 14.16 mL). The mixture was stirred at 20 °C for 30 min. The mixture was diluted with water (40 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phase was washed with brine (2 x 25 mL), dried with anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was triturated with petroleum ether (2 x 20 mL) to give 2-(2,6-dioxo-3-piperidyl)-4-[[4-(hydroxymethyl)phenyl]methoxy]isoindoline-1,3-dione (1.20 g, 3.04 mmol, 85.9% yield) as a white solid. ¹H NMR (DMSO-*d*₆, 400MHz) δ 11.13 (s, 1H), 7.82 (dd, *J* = 8.4, 7.2 Hz, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.4 – 7.45 (m, 3H), 7.36 (d, *J* = 8.0 Hz, 2H), 5.36 (s, 2H), 5.22 (t, *J* = 6.0 Hz, 1H), 5.10 (dd, *J* = 12.8, 5.4 Hz, 1H), 4.51 (d, *J* = 5.6 Hz, 2H), 2.94 – 2.85 (m, 1H), 2.62 – 2.53 (m, 2H), 2.07 – 2.01 (m, 1H).

Step B. To a solution of 2-(2,6-dioxo-3-piperidyl)-4-[[4-(hydroxymethyl)phenyl]methoxy]isoindoline -1,3-dione (600 mg, 1.52 mmol) in DMF (10.00 mL) was added methanesulfonyl chloride (970 mg, 8.47 mmol, 655.41 μL) and

1
2
3
4 DIEA (983.11 mg, 7.60 mmol, 1.33 mL) at 0 °C. The mixture was stirred at 20 °C for 2 h.

5
6
7 The reaction was quenched by addition of aqueous saturated ammonium chloride (8 mL)

8
9
10 at 0 °C. The mixture was diluted with water (30 mL) and extracted EtOAc (3 x 15 mL).

11
12
13 The combined organic phase was washed with brine (2 x 5 mL), dried with anhydrous

14
15
16 Na₂SO₄, filtered, and concentrated under reduced pressure to give crude **44** (800 mg) as

17
18
19 a yellow solid.

20
21
22
23
24
25 **4-((4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-**

26
27
28 **yl)isoindoline-1,3-dione, HCl (45)**. To a solution of **44** (180 mg, 0.381 mmol) in DMF (5.00

29
30
31 mL) was added DIEA (0.246 g, 1.90 mmol) and 1-(2,4-difluorophenyl)piperazine (113 mg,

32
33
34 0.571 mmol). The mixture was stirred at RT for 16 h. The reaction mixture was diluted

35
36
37 with water (10 mL) and extracted with EtOAc (3 x 5 mL). The combined organic phase

38
39
40 was washed with brine (2 x 5 mL), dried with anhydrous Na₂SO₄, filtered and concentrated

41
42
43 under vacuum. The residue was purified by HPLC and HCl (0.5 M, 3 mL) was added to

44
45
46 the collected fractions. Fractions containing desired product were combined and dried

47
48
49 under reduced pressure to give **45** (80 mg, 0.127 mmol, 33.5% yield, HPLC purity >97%)

1
2
3 as a white solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) \square 11.37 (s, 1H), 11.12 (s, 1H), 7.84 (dd,
4
5
6
7 $J= 8.4, 7.6$ Hz, 1H), 7.72 (d, $J= 8.4$ Hz, 2H), 7.63 – 7.59 (m, 3H), 7.49 (d, $J=7.6$ Hz, 1H),
8
9
10 7.25 (ddd, $J= 12.4, 9.2, 2.8$ Hz, 1H), 7.12 (td, $J= 9.2, 6.0$ Hz, 1H), 7.05 – 7.00 (m, 1H),
11
12
13 5.42 (s, 2H), 5.10 (dd, $J= 12.8, 5.6$ Hz, 1H), 4.39 (d, $J= 4.8$ Hz, 2H), 3.42 – 3.32 (m, 4H),
14
15
16
17 3.24 – 3.16 (m, 4 H), 2.93 – 2.84 (m, 1H), 2.61 – 2.52 (m, 2H), 2.07 – 2.01 (m, 1H); MS
18
19
20
21 (ESI) m/z 575.3 $[\text{M}+1]^+$.
22
23
24

25 **2-(2,6-Dioxopiperidin-3-yl)-4-((4-((4-(4-fluorophenyl)piperazin-1-**

26
27
28 **yl)methyl)benzyl)oxy)isoindoline-1,3-dione (46).** *Step A.* A suspension of 2-(2,6-
29
30 dioxopiperidin-3-yl)-4-(4-(hydroxymethyl)benzyloxy)isoindoline-1,3-dione (1.05 g, 2.66
31
32
33 mmol) in a mixture of DCM and ACN (25 mL, 10 mL) was stirred in an ice bath. To the
34
35
36 mixture was added PBr_3 (0.502 mL, 5.32 mmol) in one portion. After 5 min, the ice bath
37
38
39 was removed and the reaction mixture was stirred at room temperature for 20 h. To the
40
41
42 reaction mixture was added NaBr (0.822 g, 7.99 mmol) and tetrabutylammonium bromide
43
44
45 (0.077 g, 0.240 mmol) and stirring was continued for an additional 14 h at RT. The
46
47
48
49
50
51
52
53 reaction was concentrated under reduced pressure to an off-white solid. The solid was
54
55
56
57
58
59
60

1
2
3
4 slurried in water and filtered. The cake was washed with water and dried to give 4-((4-
5
6
7 (bromomethyl) benzyl)-oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione as a white
8
9
10 solid (1.21 g, 99% yield). ¹H NMR (DMSO-*d*₆) δ 11.11 (s, 1H), 7.83 (dd, *J* = 7.3, 8.4 Hz,
11
12
13 1H), 7.59 (d, *J* = 8.5 Hz, 1H), 7.38 – 7.54 (m, 5H), 5.38 (s, 2H), 5.10 (dd, *J* = 5.4, 12.9 Hz,
14
15 1H), 5.10 (dd, *J* = 5.4, 12.9 Hz, 1H), 4.72 (s, 2H), 2.79 – 2.99 (m, 1H), 2.42 – 2.70 (m, 2H),
16
17 1.94 – 2.15 (m, 1H); MS (ESI) *m/z* 479 [M+Na]⁺.
18
19
20
21
22
23
24

25
26 *Step B.* To a suspension of 4-(4-(bromomethyl)benzyloxy)-2-(2,6-dioxopiperidin-3-
27
28 yl)isoindoline-1,3-dione (0.25 g, 0.547 mmol) in DCM was added 1-(4-
29
30 fluorophenyl)piperazine (0.108 g, 0.601 mmol) and DIEA (0.212 g, 1.640 mmol). The
31
32 mixture was stirred at RT overnight. To the reaction mixture was added water (10 mL)
33
34 and DCM (15 mL) and extracted. The organic layer was concentrated then purified by
35
36 silica gel column chromatography to give **46** as a yellow solid (0.24 g, 79% yield, HPLC
37
38 purity >99%). ¹H NMR (DMSO-*d*₆) δ 11.11 (s, 1H), 7.83 (dd, *J* = 7.4, 8.5 Hz, 1H), 7.61 (d,
39
40 *J* = 8.5 Hz, 1H), 7.42 – 7.55 (m, 3H), 7.29 – 7.41 (m, 2H), 6.97 – 7.15 (m, 2H), 6.80 – 6.97
41
42 (m, 2H), 5.36 (s, 2H), 5.09 (dd, *J* = 5.4, 12.7 Hz, 1H), 3.53 (s, 2H), 2.98 – 3.19 (m, 4H),
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 2.79 – 2.97 (m, 1H), 2.54 – 2.67 (m, 5H), 2.41 – 2.47 (m, 1H), 1.92 – 2.13 (m, 1H); ¹³C
5
6
7 NMR (DMSO-*d*₆) δ 21.95, 30.90, 48.75, 48.97, 52.51, 61.65, 69.96, 115.03, 115.31,
8
9
10 115.50, 116.98, 117.09, 120.21, 127.28, 129.00, 133.26, 134.79, 136.97, 137.94, 147.92,
11
12
13 154.35, 155.53, 157.47, 165.29, 166.75, 169.87, 172.71; Anal Calcd for
14
15 C₃₁H₂₉N₄O₅+0.2 H₂O: C, 66.47; H, 5.29; N, 10.00; Found: C, 66.16; H, 5.17; N, 9.93;
16
17
18 mp: 135 – 137 °C.
19
20
21
22
23
24

25 **4-((4-((4-(2,4-Dichlorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-2-(2,6-dioxopiperidin-3-**
26
27
28 **yl)isoindoline-1,3-dione, HCl (47)**. To a solution of **44** (180 mg, 0.380 mmol) in DMF (5.00
29
30 mL) was added DIEA (0.246 g, 1.90 mmol) and 1-(2,4-dichlorophenyl)piperazine (132
31
32 mg, 0.571 mmol). The mixture was stirred at RT for 16 h. The reaction mixture was diluted
33
34 with water (10 mL) and extracted with EtOAc (3 x 5 mL). The combined organic phase
35
36 was washed with brine (2 x 5 mL), dried with anhydrous Na₂SO₄ filtered and concentrated
37
38 under vacuum. The residue was purified by HPLC and HCl (0.5 M, 3 mL) was added to
39
40 the collected fractions. Fractions containing desired product were combined and dried
41
42 under reduced pressure to give **47** (0.089 g, 0.138 mmol, 36.1% yield, HPLC purity >99%)
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 as a white solid. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.26 (s, 1H), 11.12 (s, 1H), 7.85 (dd,
4
5
6
7 $J = 8.4, 7.6$ Hz, 1H), 7.72 (d, $J = 6.4$ Hz, 2H), 7.63 – 7.59 (m, 4H), 7.49 (d, $J = 7.2$ Hz,
8
9
10
11 1H), 7.40 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.20 (d, $J = 8.8$ Hz, 1H), 5.42 (s, 2H), 5.10 (dd, $J =$
12
13
14 12.8, 5.6 Hz, 1H), 4.42 (d, $J = 4.8$ Hz, 2H), 3.43 – 3.35 (m, 4H), 3.23 – 3.15 (m, 4H), 2.93
15
16
17 – 2.84 (m, 1H), 2.61 – 2.52 (m, 2H), 2.07 – 2.01 (m, 1H); MS (ESI) m/z 607.2 $[\text{M}+1]^+$.
18
19
20
21

22 **4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzaldehyde (49)**. To a mixture of 1-
23
24
25
26 (2,4-difluorophenyl)piperazine (179 mg, 0.904 mmol) and 4-(bromomethyl)benzaldehyde
27
28
29 **(48)** (150 mg, 0.754 mmol) in ACN (5.0 mL) was added TEA (0.153 g, 1.51 mmol) in one
30
31
32
33 portion at 25 °C under nitrogen. The mixture was stirred at 25 °C for 16 h. The
34
35
36
37 mixture was poured into ice-water (20 mL) and stirred for 5 min. The aqueous phase was
38
39
40
41 extracted with EtOAc (3 x 15 mL). The combined organic phase was washed with brine
42
43
44 (2 x 15 mL), dried with anhydrous Na_2SO_4 , filtered and concentrated under vacuum. The
45
46
47
48 resulting residue was purified by silica gel column chromatography to give **49** (0.228 g,
49
50
51 0.721 mmol, 95% yield) as a yellow oil. MS (ESI) m/z 317.1 $[\text{M}+1]^+$.
52
53
54
55
56
57
58
59
60

1
2
3
4 **3-(4-((4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)amino)-1-oxoisoindolin-2-**
5
6
7 **yl)piperidine-2,6-dione HCl (50).** A mixture of **1** (224 mg, 0.865 mmol) and **49** (228 mg,
8
9
10 0.721 mmol) in acetic acid (10.00 mL) was stirred at 100 °C for 3 h under nitrogen. The
11
12
13
14 reaction mixture was cooled to 25 °C and sodium borohydride (0.054 g, 1.44 mmol) was
15
16
17 added. The reaction mixture was stirred at 25 °C for 30 min under nitrogen. The mixture
18
19
20
21 was concentrated under reduced pressure and the resulting residue was purified by
22
23
24 HPLC to give **50** (215 mg, 0.351 mmol, 48.6% yield, HPLC purity >97%) as yellow
25
26
27 solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.66 (s, 1H), 11.04 (s, 1H), 7.64 (d, *J* = 8.2 Hz,
28
29
30
31 2H), 7.48 (d, *J* = 8.2 Hz, 2H), 7.29 – 7.20 (m, 2H), 7.16 – 7.08 (m, 2H), 7.01 – 6.98 (m,
32
33
34 1H), 6.69 (d, *J* = 8.0 Hz, 1H), 5.13 (dd, *J* = 5.2, 13.2 Hz, 1H), 4.44 (s, 2H), 4.40 – 4.30 (m,
35
36
37 3H), 4.26 – 4.18 (m, 1H), 3.43 – 3.28 (m, 4H), 3.28 – 3.09 (m, 4H), 3.01 – 2.87 (m, 1H),
38
39
40
41 2.63 (d, *J* = 16.8 Hz, 1H), 2.36 – 2.26 (m, 1H), 2.10 – 2.01 (m, 1H); MS (ESI) *m/z* 560.3
42
43
44
45 [M+1]⁺.
46
47
48
49

50 **Methyl (2*S*)-2-[(*E*)-benzylideneamino]propanoate (52).** To a mixture of methyl (2*S*)-2-
51
52
53 aminopropanoate HCl (**51**) (20.0 g, 143.3 mmol), MgSO₄ (12.07 g, 100.3 mmol) and TEA
54
55
56
57
58
59
60

1
2
3
4 (17.40 g, 171.9 mmol, 23.84 mL) in DCM (200 mL) was added benzaldehyde (15.21 g,
5
6
7 143.29 mmol). The reaction was stirred at 15 °C for 16 h. The mixture was filtered and
8
9
10 the filtrate washed with brine (3 x 200 mL). The organic layer was dried over anhydrous
11
12
13 Na₂SO₄, filtered, and the solvent was evaporated under vacuum to give crude **52** (22.00
14
15
16 g), obtained as a yellow oil. The residue was used in the next step without further
17
18
19
20
21 purification.

22
23
24 **3-Amino-3-methyl-piperidine-2,6-dione HCl (53)**. *Step A*. To a mixture of **52** (22.00 g,
25
26
27 115.04 mmol) and prop-2-enamide (12.27 g, 172.56 mmol, 11.91 mL) in THF (400 mL)
28
29
30
31 was added t-BuOK (14.20 g, 126.54 mmol) in portions over 20 min at 5 °C. The reaction
32
33
34 was stirred at 0 °C for 15 min. Solid ammonium chloride (6.77 g, 126.54 mmol) was
35
36
37 added in portions and the mixture was stirred at 0 °C for another 15 min. The mixture was
38
39
40 poured into ice water (400 mL) and evaporated under vacuum to ~400 mL. The resulting
41
42
43 solid was collected by vacuum filtration and dried under vacuum to give 3-[(*E*)-
44
45
46 benzylideneamino]-3-methyl-piperidine-2,6-dione (20.00 g, 86.86 mmol, 75.5% yield) as
47
48
49
50
51
52
53 a white solid. The residue was used in the next step without further purification.
54
55
56
57
58
59
60

1
2
3
4 *Step B.* To a mixture of 3-[(*E*)-benzylideneamino]-3-methyl-piperidine-2,6-dione (20.00 g,
5
6
7 86.86 mmol) in THF (200 mL) was added aqueous HCl (4 M, 26 mL) at 0 °C. The mixture
8
9
10 was stirred at 10 °C for 3 h. The mixture was filtered. The solvent was removed under
11
12
13 reduced pressure. The resulting residue was washed with EtOAc (20 mL) and dried to
14
15
16
17 give **53** (15.0 g, 83.98 mmol, 96% yield) as a white solid.
18
19
20
21

22 **[(1*S*,2*R*,5*S*)-2-Isopropyl-5-methyl-cyclohexyl]** **N-[(3*S*)-3-methyl-2,6-dioxo-3-**
23
24
25 **piperidyl]carbamate (55).** To a mixture of **53** (15.0 g, 83.98 mmol) in THF (250 mL) and
26
27
28 water (250 mL) was added **[(1*S*,2*R*,5*S*)-2-isopropyl-5-methyl-cyclohexyl]**
29
30
31
32 carbonochloridate (**54**) (19.29 g, 88.18 mmol) at 0 °C. NaHCO₃ (28.22 g, 335.92 mmol)
33
34
35
36 was added and the mixture was stirred at 0 °C for 2 h. The reaction mixture was extracted
37
38
39 with EtOAc (3 x 500 mL). Organic layers were combined and volatile organics were
40
41
42 removed under reduced pressure. The resulting residue was purified by silica gel column
43
44
45 chromatography. The isolated solid was dissolved in EtOAc (30 mL) and heated to 80 °C
46
47
48 for 30 min. The mixture was cooled to 0 °C and filtered. The solid was dissolved in EtOAc
49
50
51
52
53 (20 mL) and heated to 80 °C for 30 min once more. The solvent was cooled to 0 °C. The
54
55
56
57
58
59
60

1
2
3 mixture became a white suspension. The mixture was filtered, and the resulting white
4
5
6
7 solid was dried to give **55** (2.50 g, 7.71 mmol, 9.2% yield). MS (ESI) m/z 347.1 [M+Na]⁺;
8
9
10 SFC 1.68 min(>99.8% ee).

11
12
13
14 **(3S)-3-Amino-3-methyl-piperidine-2,6-dione HBr (56)**. To a mixture of **55** (2.50 g, 7.71
15
16
17 mmol) in AcOH (25 mL) was added HBr (25 mL) under nitrogen. The mixture was stirred
18
19
20
21 at 90 °C for 6 h. The mixture was cooled to 15 °C and stirred for 30 min. The mixture was
22
23
24 filtered and the collected solids were washed with AcOH (3 x 10 mL) and EtOAc (3 x 15
25
26
27 mL). The remaining solid was dried to give **56** (1.50 g, 6.72 mmol, 87.2% yield). VCD
28
29
30
31 analysis confirms absolute configuration of S with 99% confidence. ¹H NMR (400 MHz,
32
33
34 DMSO-*d*₆) δ 11.31 (s, 1H), 8.61 (br s, 3H), 2.85 – 2.76 (m, 1H), 2.69 – 2.57 (m, 1H), 2.22
35
36
37
38 (dt, *J* = 5.4, 13.2 Hz, 1H), 2.11 – 2.01 (m, 1H), 1.53 (s, 3H).

39
40
41
42
43 **(3S)-3-[4-[*tert*-Butyl(dimethyl)silyl]oxy-1-oxo-isoindolin-2-yl]-3-methyl-piperidine-2,6-**
44
45
46 **dione (57)**. *Step A*. A mixture of **10** (1.610 g, 4.48 mmol), **56** (1.500 g, 6.72 mmol) and
47
48
49 DIEA (1.740 g, 13.44 mmol) in ACN (30 mL) was stirred at 15 °C for 16 h. The mixture
50
51
52
53 was extracted with EtOAc (3 x 50 mL). The organic layer was dried over anhydrous
54
55
56
57
58
59
60

1
2
3 Na₂SO₄ and solvent was evaporated under vacuum. The residue was purified by silica
4
5
6
7 gel column chromatography to give crude methyl 3-[*tert*-butyl(dimethyl)silyl]oxy-2-[[[(3*S*)-
8
9
10 3-methyl-2,6-dioxo-3-piperidyl]amino]methyl]benzoate (1.20 g) as a yellow oil. MS (ESI)
11
12
13
14 *m/z* 421.2 [M+1]⁺.
15
16
17

18 Step B. To a mixture of methyl 3-[*tert*-butyl(dimethyl)silyl]oxy-2-[[[(3*S*)-3-methyl-2,6-
19
20
21 dioxo-3-piperidyl]amino]methyl]benzoate (1.200 g, 2.85 mmol) in toluene (15 mL) was
22
23
24 added trimethylaluminum (2 M, 0.14 mL) at 15 °C. The mixture was stirred at 110 °C for
25
26
27
28 2 h. The solvent was evaporated under vacuum and the residue was purified by silica gel
29
30
31 column chromatography to give **57** (0.600 g, 1.54 mmol, 54.2% yield) as a yellow solid.
32
33
34
35 MS (ESI) *m/z* 389.0 [M+1]⁺.
36
37
38

39 **(*S*)-3-(4-((4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-
40
41
42 yl)-3-methylpiperidine-2,6-dione (58)**. To a mixture of 1-[[4-(bromomethyl)phenyl]methyl]-
43
44
45 4-(2,4-difluorophenyl)piperazine HBr (**63**) (0.711 g, 1.54 mmol) and **57** (0.600 g, 1.54
46
47
48 mmol) in DMF (5 mL) was added K₂CO₃ (0.641 g, 4.63 mmol) at 15 °C. The mixture was
49
50
51
52
53 stirred at 15 °C for 16 h. The mixture was filtered and the solvent was evaporated under
54
55
56
57
58
59
60

1
2
3 vacuum. The residue was purified by HPLC to give a white solid. The solid was further
4
5
6
7 purified by preparative chiral HPLC to give **58** (0.221 g, 0.38 mmol, 73.7% yield, HPLC
8
9
10 purity >98%) as a white solid. ¹H NMR (400MHz, DMSO-*d*₆) δ 10.85 (br s, 1H), 7.56 –
11
12 7.43 (m, 3H), 7.42 – 7.29 (m, 3H), 7.27 – 7.13 (m, 2H), 7.11 – 6.92 (m, 2H), 5.26 (br s,
13
14 2H), 4.75 – 4.52 (m, 2H), 3.55 (br s, 2H), 2.97 (br s, 4H), 2.82 – 2.55 (m, 7H), 1.89 (br d,
15
16
17
18
19
20
21 *J* = 11.9 Hz, 1H), 1.69 (s, 3H); MS (ESI) *m/z* 575.3 [M+1]⁺; SFC 3.41 min(>99.8% ee).
22
23

24
25 **(*R*)-3-(4-(((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-**
26
27
28 **yl)-3-methylpiperidine-2,6-dione (59)**. The title compound (0.109 g, 0.19 mmol, 21.4%
29
30
31 yield, HPLC purity >98%) was obtained as a white solid which originated from the same
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
59. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.54 (br. s., 1H), 10.87 (s, 1H), 7.72 (d, *J* = 8.2 Hz,
2H), 7.61 (d, *J* = 8.0 Hz, 2H), 7.50 – 7.43 (m, 1H), 7.35 – 7.21 (m, 3H), 7.13 (dt, *J* = 5.8,
9.4 Hz, 1H), 7.07 – 6.99 (m, 1H), 5.38 – 5.27 (m, 2H), 4.77 – 4.56 (m, 2H), 4.44 – 4.35

(m, 2H), 3.48 – 3.30 (m, 5H), 3.22 (d, $J = 8.3$ Hz, 4H), 2.81 – 2.58 (m, 2H), 1.96 – 1.85 (m, 1H), 1.70 (s, 3H); MS (ESI) m/z 575.3 $[M+1]^+$; SFC 4.05 min(>99.8% ee).

(S/R)-3-(4-((4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (60, 61). Compounds **60** and **61** resulted from the chiral separation of racemic compound **13** (0.300 g, 0.535 mmol) using preparative chiral HPLC.

The conditions used are as follows:

Isocratic Method: 15% B in 40 min. Column: Astec_Chirobiotik_V2, 21.2 x 250mm, 5 μ . A: 0.1% formic acid in water, B: 0.1% formic acid in ACN.

Fractions containing the desired product were combined and volatile organics were removed under reduced pressure to give (S)-3-(4-((4-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**60**) (0.135 g, 0.234 mmol, 45.0% yield, HPLC purity >99%, ee > 99%) and (R)-3-(4-((4-((4-(2,4-difluorophenyl)piperazin-1-yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione (**61**) (0.131 g, 0.241 mmol, 43.7% yield, HPLC purity > 99%, ee > 99%) as white

1
2
3
4 solids. Absolute stereochemistry of **60** was later confirmed by resynthesis using the chiral
5
6
7 synthetic route described in scheme 8.
8
9

10
11 **60**: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.97 (br s, 1H), 7.41– 7.54 (m, 3H), 7.30 – 7.39 (m,
12
13 4H), 7.17 (ddd, $J = 2.81, 9.17, 12.35$ Hz, 1H), 7.01 – 7.10 (m, 1H), 6.93 – 7.01 (m, 1H),
14
15 5.24 (s, 2H), 5.11 (dd, $J = 5.01, 13.33$ Hz, 1H), 4.37 – 4.48 (m, 1H), 4.21 – 4.31 (m, 1H),
16
17 3.54 (s, 2H), 2.84 – 3.00 (m, 5H), 2.54 – 2.61 (m, 5H), 2.37 – 2.47 (m, 1H), 1.92 – 2.04
18
19 (m, 1H); MS (ESI) m/z 561.2[M+1] $^+$.
20
21
22
23
24
25
26

27
28 **61**: ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 10.97 (s, 1H), 7.42 – 7.53 (m, 3H), 7.29 – 7.39 (m,
29
30 4H), 7.17 (ddd, $J = 2.87, 9.17, 12.41$ Hz, 1H), 7.01 – 7.10 (m, 1H), 6.94 – 7.01 (m, 1H),
31
32 5.24 (s, 2H), 5.11 (dd, $J = 5.01, 13.20$ Hz, 1H), 4.36 – 4.47 (m, 1H), 4.20 – 4.31 (m, 1H),
33
34 3.54 (s, 2H), 2.84 – 3.01 (m, 5H), 2.59 (br s, 5H), 2.35 – 2.47 (m, 1H), 1.92 – 2.04 (m,
35
36 1H); MS (ESI) m/z 561.2[M+1] $^+$.
37
38
39
40
41
42
43
44
45
46
47
48

49
50 **(4-((4-(2,4-Difluorophenyl)piperazin-1-yl)methyl)phenyl)methanol (62)**. To a mixture of **49**
51
52
53 (1.70 g, 5.37 mmol) in MeOH (20 mL) was added sodium borohydride (0.30 g, 8.06 mmol)
54
55
56
57
58
59
60

1
2
3
4 at 0 °C. The mixture was stirred at 0 °C for 2 h. The solvent was evaporated under vacuum
5
6
7 and the remaining residue was washed with water (3 x 10 mL) to give **62** (1.500 g, 4.71
8
9
10 mmol, 87.7% yield) as a yellow oil. MS (ESI) m/z 319.1 [M+1]⁺.
11
12
13

14 **1-[[4-(Bromomethyl)phenyl]methyl]-4-(2,4-difluorophenyl)piperazine HBr (63)**. To a
15
16 mixture of **62** (1.500 g, 4.71 mmol) in DCM (20 mL) was added thionyl bromide (1.960 g,
17
18 9.42 mmol, 0.73 mL) at 15 °C. The mixture was stirred at 15 °C for 2 h. Petroleum ether
19
20
21 (20 mL) was added to the reaction mixture and the mixture was filtered. The collected
22
23
24
25 solid was dried under vacuum to give **63** (2.00 g, 4.33 mmol, 91.9% yield) as a yellow
26
27
28
29 solid. MS (ESI) m/z 381.0 [M+1]⁺.
30
31
32
33
34
35

36 **tert-Butyl-4-[[2-(1-carbamoyl-4-methoxy-4-oxo-butyl)-1-oxo-isoindolin-4-**
37
38
39 **yl]oxymethyl]benzoate (65)**. To a suspension of **11** (210.0 g, 718.46 mmol) and tert-butyl
40
41
42 4-(bromomethyl)benzoate (**64**) (194.81 g, 718.46 mmol) in NMP (2.10 L) was
43
44
45 added K₂CO₃ (297.90 g, 2.16 mol). The reaction mixture was stirred at 25 °C for 4 h, then
46
47
48
49 was poured into water (3 L), extracted with EtOAc (3 x 5 L). The organic phase was
50
51
52
53 washed with brine (5 L), dried with Na₂SO₄, and concentrated under reduced pressure.
54
55
56
57
58
59
60

1
2
3
4 During the process of concentration, a white solid was formed. Collected by filtration, the
5
6
7 filter cake was washed with a 1:1 mixture of petroleum ether;EtOAc (350 mL), to give
8
9
10 after drying **65** (200.0 g, 414.9 mmol, 57.7% yield) as white solid. ¹H NMR (400 MHz,
11
12
13 DMSO-*d*₆) □ 7.93 (d, *J* = 8.38 Hz, 2H), 7.61 (d, *J* = 7.94 Hz, 3H), 7.41 – 7.48 (m, 1H),
14
15
16
17 7.28 (dd, *J* = 7.94, 18.52 Hz, 2H), 7.21 (s., 1H), 5.34 (s, 2H), 4.74 (dd, *J* = 4.85, 10.14 Hz,
18
19
20 1H), 4.54 – 4.61 (m, 1H), 4.41 – 4.48 (m, 1H), 3.50 (s, 3H), 3.29 (t, *J* = 6.84 Hz, 1H), 2.69
21
22
23
24 (s, 1H), 2.23 – 2.30 (m, 2H), 2.14 – 2.23 (m, 1H), 2.02 – 2.12 (m, 1H), 1.89 (m, 1H), 1.54
25
26
27
28 (s, 9H). MS (ESI) *m/z* 483 [M+1]⁺.

29
30
31
32 ***tert*-Butyl 4-[[2-(2,6-dioxo-3-piperidyl)-1-oxo-isoindolin-4-yl]-oxymethyl]benzoate (66)**. A
33
34
35 solution of **65** (99.60 g, 206.42 mmol) in THF (3.00 L) was cooled in a dry ice/acetone
36
37
38 bath to -70 °C. While stirring, *t*-BuOK (25.48 g, 227.06 mmol) was added in one portion
39
40
41
42 to the clear solution. The reaction mixture turned pale yellow and was stirred for 1.5 h at
43
44
45
46 -70 °C. A cooled 1N aqueous solution of HCl (900 mL) was rapidly added to the reaction
47
48
49
50 mixture while maintaining the temperature at -70 °C. The mixture immediately turned
51
52
53 milky white and the dry ice-acetone bath was removed. The mixture was concentrated to
54
55
56
57
58
59
60

1
2
3
4 remove most of the THF. Upon concentration, a white solid precipitated out. The solid
5
6
7 was collected by vacuum filtration and the filter cake was washed with water (200 mL).
8
9
10 The material was dried to give **66** (68.34 g, 151.7 mmol, 73.5% yield) as a white solid. ¹H
11
12
13 NMR (400 MHz, DMSO-*d*₆) □ 10.99 (s, 1H), 7.92 (d, *J* = 8.22 Hz, 2H), 7.60 (d, *J* = 8.22
14
15
16 Hz, 2H), 7.44 – 7.51 (m, 1H), 7.31 (dd, *J* = 7.83, 19.56 Hz, 2H), 5.35 (s, 2H), 5.12 (dd, *J*
17
18 = 5.09, 13.30 Hz, 1H), 4.41 – 4.49 (m, 1H), 4.26 – 4.34 (m, 1H), 2.85 – 2.98 (m, 1H), 2.59
19
20
21 (d, *J* = 17.61 Hz, 1H), 2.38 – 2.48 (m, 1H), 2.01 (s, 1H), 1.54 (s, 9H).
22
23
24
25
26
27
28

29 **Perfluorophenyl** 4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-
30
31 yl)oxy)methyl)benzoate (**67**). *Step A.* To a mixture of **66** (350.0 g, 776.95 mmol) in DCM
32
33 (1.22 L) was added TFA (1.88 kg, 16.51 mol, 1.22 L). The mixture was stirred at 25 °C
34
35
36 for 12 h. The reaction mixture was filtered and the filter cake was washed with DCM (3 x
37
38
39 500 mL). The filtrate was concentrated and filtered. The resulting filter cake was washed
40
41
42 with DCM (3 x 200 mL). The two solids were combined and dried to give 4-(((2-(2,6-
43
44
45 dioxopiperidin-3-yl)-1-oxoisindolin-4-yl)oxy)methyl)benzoic acid (325.0 g, 824 mmol,
46
47
48
49 100% yield) as white solid. ¹H NMR (400 MHz, DMSO-*d*₆) □ 10.98 (s, 1H), 7.97 (d, *J* =
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 7.94 Hz, 2H), 7.61 (d, J = 7.94 Hz, 2H), 7.45 – 7.52 (m, 1H), 7.32 (dd, J = 7.72, 13.45 Hz,
5
6
7 2H), 5.35 (s, 2H), 5.12 (dd, J = 4.85, 13.23 Hz, 1H), 4.41 – 4.50 (m, 1H), 4.26 – 4.35 (m,
8
9
10 1H), 2.84 – 2.98 (m, 1H), 2.58 (d, J = 18.08 Hz, 1H), 2.39 – 2.46 (m, 1H), 1.94 – 2.04 (m,
11
12
13 1H). MS (ESI) m/z 393 [M-1]⁺.
14
15
16
17

18 *Step B.* Perfluorophenyl 2,2,2-trifluoroacetate (0.805 mL, 4.68 mmol) was added to a
19
20
21 heterogeneous solution of 4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-4-
22
23
24 yl)oxy)methyl)benzoic acid (739 mg, 1.874 mmol) in THF (5 mL), and DIEA (1.3 mL, 7.44
25
26
27 mmol) at RT. DMF (10.0 mL) was added in portions until the solution was pink and
28
29
30
31 homogeneous. The reaction was diluted with water (5 mL) giving a copious white
32
33
34 precipitate. The precipitate was collected by filtration, washed with water, and dried to
35
36
37 provide **67** (598.1 mg, 1.067 mmol, 57.0% yield) as a light grey solid. MS (ESI) m/z 561.2
38
39
40
41
42 [M+1]⁺.
43
44
45

46 **3-(4-((4-(4-(2,4-Difluorophenyl)piperazine-1-carbonyl)benzyl)oxy)-1-oxoisindolin-2-
47
48
49 yl)piperidine-2,6-dione (68).** A flask containing **67** (407 mg, 0.726 mmol) and 1-(2,4-
50
51
52 difluorophenyl)piperazine (309 mg, 1.559 mmol) was treated with DMF (2.0 mL) and DIEA
53
54
55
56
57
58
59
60

(0.254 mL, 1.452 mmol) for 10 min. The reaction mixture was purified directly by semi-preparative HPLC to provide **68** (310.9 mg, 0.541 mmol, 74.5% yield, HPLC purity >99%) as a white powder. ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.59 (d, *J* = 8.20 Hz, 2H), 7.43 – 7.54 (m, 3H), 7.35 (dd, *J* = 7.88, 1.89 Hz, 2H), 7.22 (ddd, *J* = 12.30, 9.14, 2.84 Hz, 1H), 7.11 (td, *J* = 9.46, 5.99 Hz, 1H), 7.02 (td, *J* = 8.35, 2.21 Hz, 1H), 5.32 (s, 2H), 5.13 (dd, *J* = 13.40, 5.20 Hz, 1H), 4.46 (d, *J* = 17.34 Hz, 1H), 4.30 (d, *J* = 17.65 Hz, 1H), 3.66 – 3.88 (m, 2H), 3.37 – 3.60 (m, 2H), 2.84 – 3.11 (m, 5H), 2.54 – 2.69 (m, 2H), 2.46 (d, *J* = 8.83 Hz, 2H), 1.94 – 2.04 (m, 1H); MS (ESI) *m/z* 575.2 [M+1]⁺.

3-(4-((4-(4-(4-Fluorophenyl)piperazine-1-carbonyl)benzyl)oxy)-1-oxoisindolin-2-

yl)piperidine-2,6-dione (69). A solution of **67** (100 mg, 0.178 mmol) in DMF (1.0 mL) was added to a vial containing 1-(4-fluorophenyl)piperazine (50.8 mg, 0.282 mmol), DIEA (0.060 mL, 0.344 mmol), and DMF (0.5 mL) for 10 min. The reaction mixture was purified by semi-preparative HPLC to give **69** (73.6 mg, 0.132 mmol, 74.1% yield, HPLC purity >99%) as a white solid. ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.59 (d, *J* = 8.20 Hz, 2H), 7.49 – 7.54 (m, 1H), 7.48 (d, *J* = 8.20 Hz, 2H), 7.35 (dd, *J* = 7.88, 2.84 Hz, 2H), 7.04 – 7.13 (m, 2H), 6.94 – 7.02 (m, 2H), 5.32 (s, 2H), 5.13 (dd, *J* = 13.40, 5.20 Hz, 1H),

1
2
3 4.46 (d, $J = 17.34$ Hz, 1H), 4.30 (d, $J = 17.34$ Hz, 1H), 3.76 (br. s., 2H), 3.49 (br. s., 2H),
4
5
6
7 3.11 (br. s., 4H), 2.92 (ddd, $J = 17.50, 13.56, 5.52$ Hz, 1H), 2.54 – 2.68 (m, 1H), 2.35 –
8
9
10 2.48 (m, 1H), 1.94 – 2.05 (m, 1H); MS (ESI) m/z 557.2 $[M+1]^+$.

11
12
13
14
15
16
17 **3-(4-((4-(4-(4-Chlorophenyl)piperazine-1-carbonyl)benzyl)oxy)-1-oxoisindolin-2-**

18 **yl)piperidine-2,6-dione (70).** A portion of **67** (102.1 mg, 0.182 mmol) was added to a vial
19
20
21 containing 1-(4-chlorophenyl)piperazine (45.7 mg, 0.232 mmol), DIEA (0.08 mL, 0.458
22
23
24 mmol), and DMF (1.5 mL). The reaction was heated to 60 °C for 10 min. The reaction
25
26
27
28 mixture was purified by semi-preparative HPLC to give **70** (54.1 mg, 0.094 mmol, 51.8%
29
30
31 yield, HPLC purity >99%) as a white solid. ^1H NMR (500 MHz, $\text{DMSO-}d_6$) δ 10.97 (s, 1H),
32
33
34 7.59 (d, $J = 8.51$ Hz, 2H), 7.43 – 7.55 (m, 3H), 7.35 (dd, $J = 7.88, 2.52$ Hz, 2H), 7.20 –
35
36
37 7.29 (m, 2H), 6.92 – 7.03 (m, 2H), 5.32 (s, 2H), 5.13 (dd, $J = 13.24, 5.04$ Hz, 1H), 4.46 (d,
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 $J = 17.34$ Hz, 1H), 4.30 (d, $J = 17.34$ Hz, 1H), 3.75 (br. s., 2H), 3.39 – 3.57 (m, 2H), 3.19
(br. s., 4H), 2.86 – 2.98 (m, 1H), 2.54 – 2.68 (m, 2H), 2.35 – 2.47 (m, 2H), 1.94 – 2.05 (m,
1H); MS (ESI) m/z 573.2 $[M+1]^+$.

1
2
3
4 **3-(4-((4-(4-(2,4-Dichlorophenyl)piperazine-1-carbonyl)benzyl)oxy)-1-oxoisindolin-2-**
5
6 **yl)piperidine-2,6-dione (71).** A solution of **67** (103.1 mg, 0.184 mmol) in DMF (1.0 mL)
7
8 was added to a vial containing 1-(2,4-dichlorophenyl)piperazine (87.1 mg, 0.377 mmol).
9
10
11 was added to a vial containing 1-(2,4-dichlorophenyl)piperazine (87.1 mg, 0.377 mmol).
12
13
14 DIEA (0.10 mL, 0.573 mmol) was added. The reaction was stirred at RT for 10 min. The
15
16
17 reaction mixture was purified by semi-preparative HPLC to give **71** (56.1 mg, 0.092 mmol,
18
19
20 50.2% yield, HPLC purity >97%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.97 (s, 1H), 7.55 –
21
22 7.61 (m, 3H), 7.46 – 7.54 (m, 3H), 7.39 (dd, *J* = 8.83, 2.52 Hz, 1H), 7.32 – 7.37 (m, 2H),
23
24 7.20 (d, *J* = 8.51 Hz, 1H), 5.32 (s, 2H), 5.13 (dd, *J* = 13.24, 5.04 Hz, 1H), 4.46 (d, *J* =
25
26 17.34 Hz, 1H), 4.30 (d, *J* = 17.65 Hz, 1H), 3.79 (br. s., 2H), 3.44 – 3.55 (m, 1H), 2.85 –
27
28 3.09 (m, 5H), 2.54 – 2.68 (m, 2H), 2.35 – 2.47 (m, 2H), 1.92 – 2.06 (m, 1H); MS (ESI) *m/z*
29
30
31 607.2 [M+1]⁺.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **4-(4-(4-(Chloromethyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (73).** 1,4-
46
47 bis(chloromethyl)benzene (51.2 g, 292 mmol) was placed in a flask with ACN (195 mL)
48
49 and DMF (195 mL) and allowed to stir at RT until all the solids dissolved. DIEA (51.1 mL,
50
51 292 mmol) was then added followed by 3-fluoro-4-(piperazin-1-yl)benzonitrile (**72**) (20 g,
52
53
54
55
56
57
58
59
60

1
2
3 97 mmol) in one portion. The reaction was heated to 60 °C for 1 h. Acetonitrile was
4
5
6 removed under reduced pressure and the remaining mixture was partitioned between
7
8
9 EtOAc (1.0 L), water (700 mL), and brine (300 mL). The organic layer was separated, and
10
11
12 the aqueous layer was extracted with EtOAc twice more. The organic layers were
13
14
15 combined and volatile organics were removed under reduced pressure. The resulting
16
17
18 solid was purified by silica gel column chromatography to give **73** (22.7 g, 66.0 mmol,
19
20
21 67.7% yield) as an off-white solid. ¹H NMR (400 MHz, CHLOROFORM-*d*) δ 7.33 – 7.39
22
23
24 (m, 5H), 7.29 (d, *J* = 1.96 Hz, 1H), 7.25 (d, *J* = 1.96 Hz, 1H), 6.91 (t, *J* = 8.56 Hz, 1H),
25
26
27 4.60 (s, 2H), 3.58 (s, 2H), 3.19 – 3.27 (m, 4H), 2.58 – 2.66 (m, 4H); MS (ESI) *m/z* 344.2
28
29
30
31
32
33
34
35 [M+1]⁺.
36
37

38 ***tert*-Butyl (4S)-5-amino-4-(4-hydroxy-1-oxo-isoindolin-2-yl)-5-oxo-pentanoate (74). Step**
39

40
41
42 A. To a solution of *tert*-butyl (4S)-4,5-diamino-5-oxo-pentanoate (130 g, 643 mmol) in
43
44
45 ACN (4.0 L) was added **10** (210 g, 584 mmol) and DIEA (113 g, 877 mmol). The reaction
46
47
48 mixture was stirred at 50 °C for 16 h, then was concentrated to remove most of the ACN.
49
50
51
52 The residue was dissolved in methyl *tert*-butyl ether (2.0 L) and water (1.5 L). The organic
53
54
55 layer was washed with saturated monopotassium phosphate (1.0 L x 2), brine (1.0 mL),
56
57
58
59
60

1
2
3
4 dried over anhydrous Na₂SO₄, filtered and concentrated to give crude tert-butyl (4S)-5-
5
6
7 amino-4-[4-[tert-butyl(dimethyl)silyl]oxy-1-oxo- isoindolin-2-yl]-5-oxo-pentanoate (524 g).
8
9

10 The material was used in the next step without further purification.
11
12
13

14 *Step B.* To a solution of tert-butyl (4S)-5-amino-4-[4-[tert-butyl(dimethyl)silyl]oxy-1-oxo-
15
16
17 isoindolin -2-yl]-5-oxo-pentanoate (275 g, 613 mmol,) in MeOH (2.0 L) was added
18
19
20
21 tetrabutylammonium fluoride trihydrate (38.7 g, 123 mmol). The mixture was stirred at 18
22
23
24 °C for 16 h. The reaction mixture was concentrated to remove most of the MeOH. The
25
26
27
28 residue was partitioned between DCM/water (3L/2L). The organic layer was washed with
29
30
31
32 brine (1.0 L), dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude material
33
34
35
36 was purified by silica gel column chromatography to give the product (260 g). The solid
37
38
39 was added into ACN (750 mL), and the mixture was stirred at 60 °C for 2 h, then cooled
40
41
42
43 to 18 °C and stirred for another 2 h. The solid was collected by filtration and the cake was
44
45
46
47 dried to give **74** (248 g, 60.5% yield) as gray solid. (Purity 100%, ee value 100%) ¹H NMR
48
49
50 (400 MHz, DMSO-*d*₆) δ 10.00 (s, 1H), 7.54 (s, 1H), 7.29 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* =
51
52
53 4.8 Hz, 2H), 4.72 – 4.68 (m, 1H), 4.49 – 4.28 (m, 2H), 2.17 – 1.97 (m, 4H), 1.31 (s, 9H).
54
55
56
57
58
59
60

1
2
3
4 **(S)-tert-Butyl** **5-amino-4-(4-((4-((4-(4-cyano-2-fluorophenyl)piperazin-1-**
5
6
7 **yl)methyl)benzyl)oxy)-1-oxoisindolin-2-yl)-5-oxopentanoate (75)**. A portion of **74** (22.05
8
9
10 g, 65.9 mmol) was placed in a flask with **73** (22.67 g, 65.9 mmol), K₂CO₃ (18.23 g, 132
11
12
13 mmol), and DMF (330 mL). The reaction mixture was heated to 45 °C for 16 h. The
14
15
16
17 reaction was diluted with EtOAc (50 mL) and filtered. The filtrate was partitioned with
18
19
20 EtOAc (900 mL), water (600 mL), and brine (200 mL). The organic layer was isolated and
21
22
23
24 washed again with water (600 mL). The organic layer was separated, dried over Na₂SO₄,
25
26
27
28 and volatile organics were removed under reduced pressure. The resulting residue was
29
30
31 treated with 20% EtOAc in hexanes and volatiles were removed under reduced pressure
32
33
34
35 to give **75** (44.02 g, 68.6 mmol, 100% yield) as an off-white solid. ¹H NMR (400 MHz,
36
37
38 CHLOROFORM-*d*) δ 7.43 – 7.49 (m, 2H), 7.40 (s, 4H), 7.36 (dd, *J* = 8.38, 1.28 Hz, 1H),
39
40
41
42 7.29 (d, *J* = 1.96 Hz, 1H), 7.26 (d, *J* = 1.83 Hz, 1H), 7.11 (dd, *J* = 7.64, 1.16 Hz, 1H), 6.92
43
44
45 (t, *J* = 8.50 Hz, 1H), 6.23 (br s, 1H), 5.24 – 5.32 (m, 1H), 5.15 (s, 2H), 4.86 – 4.94 (m, 1H),
46
47
48
49 4.38 – 4.55 (m, 2H), 3.61 (s, 2H), 3.18 – 3.32 (m, 4H), 2.58 – 2.70 (m, 4H), 2.09 – 2.47
50
51
52 (m, 4H), 1.43 (s, 8H); MS (ESI) *m/z* 642.4 [M+1]⁺.
53
54
55
56
57
58
59
60

1
2
3
4 **(S)-4-(4-(4-(((2-(2,6-Dioxopiperidin-3-yl)-1-oxoisoindolin-4-**

5
6
7 **yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile (4)**. A portion of **75** (12.1 g,

8
9
10 18.86 mmol) was placed in a vial with ACN (190 mL) and benzenesulfonic acid (3.96 g,

11
12
13
14 24.51 mmol). The reaction mixture was placed under vacuum and purged with nitrogen.

15
16
17 This was repeated once more and the mixture was then heated to 85 °C overnight under

18
19
20 a nitrogen atmosphere. The reaction mixture was poured warm directly into 2 separatory

21
22
23 funnels containing DCM (1.0 L) and EtOAc (300 mL). To this mixture, a saturated solution

24
25
26 of NaHCO₃ (900 mL), water (100 mL), and brine (450 mL) were added. The pH of the

27
28
29 aqueous layer was tested to verify it was basic. The organic layer was isolated and the

30
31
32 aqueous layer was extracted once more with DCM (800 mL) and EtOAc (200 mL). The

33
34
35 organic layer was separated and all organic layers were combined and dried over

36
37
38 anhydrous MgSO₄, and concentrated to give a solid. To the solid was added EtOAc (400

39
40
41 mL) and hexanes (50 mL). Volatiles were removed under reduced pressure. To the

42
43
44 resulting solid was added EtOAc (150 mL) and the mixture was stirred at 40 °C for 30 min

45
46
47 until it became an homogeneous slurry. Solids were collected by vacuum filtration,

48
49
50 washed with EtOAc (100 mL), and dried to afford **4** as a white solid (7.7 g, 13.5 mmol,

1
2
3 72% yield, HPLC purity >99%, ee value >97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.96
4
5
6
7 (s, 1H), 7.68 (dd, *J* = 13.45, 1.83 Hz, 1H), 7.56 (dd, *J* = 8.44, 1.83 Hz, 1H), 7.43 – 7.52
8
9
10 (m, 3H), 7.29 – 7.39 (m, 4H), 7.11 (t, *J* = 8.80 Hz, 1H), 5.24 (s, 2H), 5.11 (dd, *J* = 13.20,
11
12
13 5.14 Hz, 1H), 4.22 – 4.46 (m, 2H), 3.54 (s, 2H), 3.12 – 3.22 (m, 4H), 2.85 – 2.97 (m, 1H),
14
15
16
17 2.53 – 2.62 (m, 2H), 2.38 – 2.48 (m, 2H), 1.93 – 2.03 (m, 1H); MS (ESI) *m/z* 568.2 [M+1]⁺.
18
19
20
21
22
23
24

25 **Fluorescence Resonance Energy Transfer-based Cereblon Binding Description:** This

26
27
28
29 assay monitors time-resolved fluorescence resonance energy transfer (TR-FRET)
30
31
32 between a Cy5-conjugated CELMoD bound in the tri-tryptophan pocket of CRBN and a
33
34
35 europium-conjugated anti-His antibody bound to a 6×His tag on the N-terminus of
36
37
38
39 CRBN. The FRET efficiency (the ratio of FRET to non-FRET emission = 665 nM/615 nM)
40
41
42 is determined by exciting the europium at 340 nM and monitoring emissions at 615 nM
43
44
45
46 (non-FRET emission) and 665 nm (FRET emission). When a competing compound is
47
48
49
50 added to displace the Cy5-conjugated CELMoD from cereblon, the FRET efficiency is
51
52
53
54
55
56
57
58
59
60

1
2
3 decreased. Consequently, the concentration-dependent loss of FRET signal can be used
4
5
6
7 to determine the IC_{50} of CRBN binding.
8
9

10 **Fluorescence Resonance Energy Transfer-based Cereblon Binding Assay:** A solution

11 containing 60 nM purified 6×His-CRBN_005-DDB1_026 (CRBN a.a. 1-442, DDB1 a.a. 1-

12
13
14
15
16
17
18 1140, generated in-house) 3 nM Eu-anti-His Tag Antibody (catalog number PV5596,

19
20
21 Thermo Fisher), and 30 nM CC0782985 was pre-mixed in FRET-assay buffer (50 mM

22
23
24 HEPES pH 7, 150 mM NaCl, 0.005% Tween 20). Thirty microliters of assay mixture were

25
26
27 distributed into the wells of white, solid bottom 384-well plates containing compounds

28
29
30 previously distributed by acoustic dispensing. The plates were then mixed on a shaker

31
32
33 for 5 seconds and spun down, with a total pre-incubation time of approximately 10

34
35
36 minutes, before scanning on a Pherastar plate reader with excitation at 340

37
38
39 nM. Emissions were monitored at 615 nM (non-FRET emission) and 665 nm (FRET

40
41
42 emission), using a 700 μ s TR-FRET delay. The FRET/non-FRET emission ratio (ratio of

43
44
45
46
47
48
49 signal from 665/615) was used to determine FRET efficiency, and the loss of FRET

1
2
3 efficiency was plotted against compound concentration to determine the relative binding
4
5
6
7 affinity (IC_{50}).
8
9

10 **ePL Degradation Description:** To monitor protein degradation, we used the DiscoverX
11
12 Enzyme Fragment Complementation Assay (EFC) technology. This system relies on
13
14 having two different components of the β -galactosidase enzyme expressed for activity.
15
16
17 The large protein fragment of β -galactosidase is included in the InCELL Hunter™
18
19
20
21 detection reagent that is added at the end of the assay. The small peptide fragment (the
22
23
24 enhanced ProLabel (ePL)) that is required for β -galactosidase activity is expressed on
25
26
27
28 the protein of interest (example: Aiolos and GSPT1). When the ePL tagged protein has
29
30
31
32 been degraded through the E3-ligase mechanism, there is a loss in the β -galactosidase
33
34
35 activity. The active β -galactosidase hydrolyzes a substrate that is turned over by
36
37
38
39 luciferase to give a chemiluminescent signal.
40
41
42
43
44

45 **ePL Degradation Assay:** DF15 multiple myeloma cells stably expressing ePL-tagged
46
47
48 Aiolos and GSPT1 were generated via lentiviral infection with pLOC-ePL-Aiolos and
49
50
51 pLOC-ePL-GSPT1. Cells were dispensed into 384-well plates (Corning #3712) that were
52
53
54
55 pre-spotted with compounds. Compounds were dispensed by an acoustic dispenser
56
57
58
59
60

1
2
3 (ATS acoustic transfer system from EDC Biosystems) into a 384-well in a 10-point
4
5
6
7 dose-response curve using a 3-fold dilution. A DMSO control is added to the assay.
8
9
10 Twenty-five microliters of media (RPMI-1640 + 10% Heat Inactivated FBS +25mM
11
12
13 Hepes+1mM Na Pyruvate+1X NEAA + 0.1% Pluronic F-68 + 1x Pen Strep Glutamine)
14
15
16
17 containing 5000 cells was dispensed per well. Assay plates were incubated at 37°C with
18
19
20
21 5% CO₂ for four hours. After incubation, 25 μL of the InCELL Hunter™ Detection Reagent
22
23
24 Working Solution (DiscoverX, cat #96-0002, Fremont, CA) was added to each well and
25
26
27
28 incubated at room temperature for 30 min protected from light. After 30 min,
29
30
31 luminescence was read on a PHERAstar luminometer (Cary, NC).
32
33
34

35 To determine the half-maximal effective concentration (EC₅₀) values for Aiolos or GSPT1
36
37
38 degradation, a four parameter logistic model was used: (Sigmoidal Dose-Response
39
40
41 Model) (FIT= (A+((B-A)/1+((C/x)^D)))) where C is the inflection point (EC₅₀), D is the
42
43
44 correlation coefficient, and A and B are the low and high limits of the fit respectively). The
45
46
47
48 lower limit of the fit (value A) is referred to as Y_{min}. A luciferase inhibitor at a concentration
49
50
51
52 of 20 μM was used as the control with a Y_{min} value = 0. The maximum limit is the Y_{max}
53
54
55
56
57
58
59
60

1
2
3
4 for the DMSO control. The curves were processed and evaluated using Activity Base
5
6
7 (IDBS).
8
9

10
11 **Immunoblot Analysis.** H929 R10-1 cells were treated with DMSO and test compounds
12
13
14 for 4h and 72h as indicated in Figure 11a. Cells were then washed with 1 X PBS and
15
16
17 lysed in Chris Buffer [0.5% NP-40 (Igepal CA-630), 50mM Tris pH 8, 10% Glycerol, 1mM
18
19
20 EDTA 200mM NaCl, complete ULTRA protease inhibitor tablet (Roche), PhosSTOP
21
22
23 phosphatase inhibitor tablet (Roche) and 0.2mM p-APMSF (Calbiochem)]. Clarified cell
24
25
26 lysates were subjected to immunoblot analysis with the following antibodies: rabbit anti-
27
28
29 Ikaros monoclonal antibody (#9034, Cell Signaling), rabbit anti-Aiolos polyclonal antibody
30
31
32 (#12720, Cell Signaling), mouse anti- β -Tubulin monoclonal antibody (#T5201, Sigma),
33
34
35 rabbit anti-IRF4 monoclonal antibody (#4299, Cell Signaling), rabbit anti-c-Myc
36
37
38 monoclonal antibody (#ab32072, Abcam), mouse anti-p27 monoclonal antibody
39
40
41 (#610241, BD Transduction Laboratories), rabbit anti-Phospho-Rb S807/811 polyclonal
42
43
44 antibody (#9308, Cell Signaling), rabbit anti-Survivin monoclonal antibody (#2808, Cell
45
46
47 Signaling), rabbit anti-BIM monoclonal antibody (#2933, Cell Signaling), rabbit anti-
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Cleaved-Caspase-1 monoclonal antibody (#4199, Cell Signaling), rabbit anti-Cleaved-
4
5
6
7 Caspase-7 polyclonal antibody (#9491, Cell Signaling), rabbit anti-Cleaved-Caspase-3
8
9
10 polyclonal antibody (#9661, Cell Signaling), rabbit anti-Cleaved-PARP monoclonal
11
12
13 antibody (#5625, Cell Signaling), goat anti-rabbit IgG (H+L) Alexa Fluor 700 (#A21038,
14
15
16 Invitrogen) and goat anti-mouse IgG (H+L) IRDye 800 (#610-132-121, Rockland).
17
18
19
20
21

22 **Growth Inhibition Assay.** H929 R10-1 cells were maintained in log-phase at 37°C with
23
24
25 5% CO₂ using the indicated media. Cell density and viability were monitored by trypan
26
27
28 blue exclusion using the Vi-Cell XR cell viability analyzer. Seeding densities were
29
30
31 established after a 5-day growth CellTiter-Glo® (CTG) assay. Compounds were
32
33
34 dispensed as 10-point duplicate DRCs starting at 10µM with (1:3) dilutions using the EDC
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 measured using the standard CTG assay which quantifies ATP production through
4
5
6 luminescence. Relative luminescence units (RLUs) were generated by dispensing 20 μ l
7
8
9
10 per well of CTG using a Multidrop™ Combi Reagent Dispenser, plates shaken for 15
11
12
13
14 seconds, incubated in the dark at room temperature for 1 hour and read on an Envision
15
16
17 luminescence detector.
18
19
20

21 **IN VIVO STUDIES**

22
23
24
25
26 **In Vivo Studies.** All animal studies were performed under protocols approved by the
27
28
29 Celgene Institutional Animal Care and Use Committee (IACUC). Animals were
30
31
32 acclimatized to the animal housing facility for a period of 7 days prior to the beginning of
33
34
35 the experiment. Female 6-8 weeks old CB17 SCID (severe combined immunodeficiency)
36
37
38 (Charles River Laboratories) mice were housed in a barrier facility in micro-isolator cages
39
40
41 at 10 animals per cage. Mice were fed with Harlan-Teklad LM- 485 Mouse/Rat Sterilizable
42
43
44 Diet and autoclaved water ad libitum and maintained on a 12 h light/dark cycle.
45
46
47
48
49

50
51 NCI-H929-1051, a lenalidomide-resistant version of NCI-H929 plasmacytoma cells
52
53
54 were generated in vitro. Parental NCI-H929 cells lines were obtained from the American
55
56
57
58
59
60

1
2
3 Tissue Culture Collection (Gaithersburg, MD). The cells were grown in growth medium
4
5
6
7 containing RPMI 1640 with 2 mM L-glutamine adjusted to contain 90% medium and 10%
8
9
10 FBS. The lenalidomide-resistant H929-1051 cell line was generated by growth in the
11
12
13 continual presence of 10 μ M lenalidomide. Cells that were expanded for implantation in
14
15
16
17 vivo were grown in the continuous presence of 10 μ M lenalidomide.
18
19
20

21 SCID mice were inoculated subcutaneously with 10×10^6 NCI-H929-1051 cells.
22
23
24 Tumor volumes were determined prior to the initiation of treatment and considered as the
25
26
27 starting volumes. Mice with tumors of approximately 150 mm³ were randomized and
28
29
30 treated orally at various doses of compound 4 (n =8–10/group). Tumors were measured
31
32
33 twice a week for the duration of the study. The long and short axes of each tumor were
34
35
36 measured using a digital caliper in millimeters and the tumor volumes were calculated
37
38
39 using the formula: width² \times length/2. The tumor volumes were expressed in cubic
40
41
42 millimeters (mm³).
43
44
45
46
47
48

49 Xenograft data are expressed as mean \pm standard error of the mean (SEM).
50
51
52 Statistical analyses were performed using GraphPad Prism. A one-way analysis of
53
54
55 variance (ANOVA) was performed for tumor volume measurements. Post-hoc analysis
56
57
58
59
60

1
2
3 was performed using Dunnett's test where all treatment groups are compared with the
4
5
6
7 vehicle control.
8
9

10 AUTHOR INFORMATION

14 Corresponding Author

15
16
17 Joshua Hansen, Tel: 858-795-4910, jhansen@celgene.com
18
19

20 Notes

21
22
23
24
25 The authors declare no competing financial interest. All authors are currently employees
26
27
28 of Celgene, except Courtney G. Havens, Veronique Plantevin, Timothy Kercher, Brian
29
30
31 Cathers, Thomas Daniel, Katerina Leftheris, and Mehran Moghaddam who were
32
33
34
35 employees of Celgene at the time of their contribution to this work.
36
37
38

39 ACKNOWLEDGMENT

40
41
42
43 Thanks to George Muller and his chemistry team for their efforts leading to the
44
45
46 development of lenalidomide and pomalidomide which served to enable starting points
47
48
49
50 and comparators for this work.
51
52
53

54 ABBREVIATIONS

1
2
3 CRBN, Cereblon; CUL4, cullin protein; DDB1, damaged DNA-binding protein 1; RBX1,
4
5
6
7 RING box-domain protein; GSPT1, G1 to S phase transition 1; DUB, deubiquitinating
8
9
10 enzyme; eRF1, eukaryotic translation termination factor 1; NBS, N-bromosuccinimide,
11
12
13
14 ACN, acetonitrile; EtOAc, ethyl acetate; HCl, hydrochloric acid; DMA,
15
16
17 dimethylacetamide; DMF, diemthylformamide; TLC, thin layer chromatography; HPLC,
18
19
20
21 high performance liquid chromatography.
22
23
24


25 ASSOCIATED CONTENT

26 27 28 29 Supporting Information.

30
31
32
33 Standard error of measurement for all biological data present and
34
35
36

37
38 Molecular Formula Strings, Excel document
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE OF CONTENTS GRAPHIC



REFERENCES

1. American Cancer Society, Cancer Statistic Center Page.

https://cancerstatisticscenter.cancer.org/?_ga=2.200904942.1379280727.1580495928-1064148705.1580495928#!/cancer-site/Myeloma (accessed Jan 2020).

2. Nijhof, I. S.; van de Donk, N.W. C. J.; Zweegman, S.; Lokhorst, H. M. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.

Drugs **2018**, *78*, 19–37.

-
- 1
2
3
4
5
6 3. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa,
7
8
9 H. Identification of a Primary Target of Thalidomide Teratogenicity. *Science* **2010**, *327*,
10
11
12
13 1345-1350.
14
15
16
17 4. Kronke, J.; Udeshi, N. D.; Narla, A.; Grauman, P.; Hurst, S. N.; McConkey, M.;
18
19
20 Svinkina, T.; Heckl, D.; Comer, C.; Li, X.; Hartman, E.; Munshi, N.; Schenone, M.;
21
22
23
24 Schreiber, S. L.; Carr, S. A.; Ebert, B. L. Lenalidomide Causes Selective Degradation of
25
26
27
28 IKZF1 and IKZF3 in Multiple Myeloma Cells. *Science* **2014**, *343*, 301-305.
29
30
31
32 5. Lu, G.; Middleton, R. E.; Sun, H.; Naniong, M.; Ott, C. J.; Mitsiades C. S.; Wong, K.
33
34
35
36 K.; Bradner, J. E.; Kaelin, W. G. Jr. The Myeloma Drug Lenalidomide Promotes the
37
38
39
40 Cereblon-Dependent Destruction of Ikaros Proteins. *Science* **2014**, *343*, 305-309.
41
42
43
44 6. Zhu, Y. X.; Braggio, E.; Shi, C. X.; Bruins, L. A.; Schmidt, J. E.; Van Wier, S.; Chang,
45
46
47
48 X-B.; Bjorklund, C.; Fonseca, R.; Bergsagel, L.; Orlowski, R.; Cereblon Expression is
49
50
51
52
53
54
55
56
57
58
59
60 Required for the Antimyeloma Activity of Lenalidomide and Pomalidomide. *Blood* **2011**,
118, 4771-4779.

1
2
3
4
5
6 7. Lopez-Girona, A.; Mendy, D.; Ito, T.; Miller, K.; Gandhi, A.K.; Kang, J.; Karasawa, S.;
7
8
9 Carmel, G.; Jackson, P.; Abbasian, M.; Mahmoudi, A.; Cathers, B.; Rychak, E.;
10
11
12 Gaidarova, S.; Chen, R.; Schafer, P.; Handa, H.; Daniel, T. Cereblon is a Direct Protein
13
14
15
16 Target for Immunomodulatory and Antiproliferative Activities of Lenalidomide and
17
18
19 Pomalidomide. *Leukemia* **2012**, *26*, 2326–2335.
20
21
22
23

24 8. Gandhi, A. K.; Kang, J.; Havens, C. G.; Conklin, T.; Ning, Y.; Wu, L.; Ito, T.; Ando,
25
26
27 H.; Waldman, M.; Thakurta, A; Klippel, A; Handa, H.; Daniel, T.; Schafer, P.; Chopra, R.
28
29
30
31 Immunomodulatory Agents Lenalidomide and Pomalidomide Co-stimulate T Cells by
32
33
34
35 Inducing Degradation of T Cell Repressors Ikaros and Aiolos via Modulation of the E3
36
37
38 Ubiquitin Ligase Complex CRL4(CRBN). *Br. J. Haematol.* **2014**, *164*, 811–821.
39
40
41

42 9. Zhu, Y. X.; Kortuem, K. M.; Stewart, A. K. Molecular Mechanism of Action of Immune-
43
44
45
46 modulatory Drugs Thalidomide, Lenalidomide and Pomalidomide in Multiple Myeloma.
47
48
49
50 *Leuk. Lymphoma.* **2013**, *54*, 683–687.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 10. Guirguis, A. A.; Ebert, B. L. Lenalidomide: Deciphering Mechanisms of Action in
7
8
9 Myeloma, Myelodysplastic Syndrome and Beyond. *Curr Opin Cell Biol.* **2015**, *37*, 61–67.

10
11
12
13
14
15
16
17
18 11. Hansen, J.D.; Condroski, K.; Correa, M.; Muller, G.; Man, H.W.; Ruchelman, A.;
19
20
21 Zhang, W.; Vocanson, F.; Crea, T.; Liu, W.; Lu, G.; Baculi, F.; LeBrun, L.; Mahmoudi, A.;
22
23
24 Carmel, G.; Hickman, M.; Lu, C.C. Protein Degradation via CRL4CRBN Ubiquitin Ligase:
25
26
27
28 Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That
29
30
31 Promote Degradation of Aiolos and/or GSPT1. *J. Med. Chem.* **2018**, *61*, 492-503.

32
33
34
35
36 12. Muller, G. W.; Ruchelman, A. L. 5-substituted Isoindoline Compounds for the use in
37
38
39
40 Cancer. WO 2010053732, **2010**.

41
42
43
44 13. Siegel, D.; Schiller, G. J.; Song, K. W.; Agajanian, R.; Stockerl-Goldstein, K.;
45
46
47 Kaya, H.; Sebag, M.; Samaras, C.; Malek, E.; Talamo, G.; Seet, C. S.; Mouro, J.;
48
49
50
51 Zafar, F.; Chung, W.; Srinivasan, S.; Qian, M.; Agarwal, A.; Thakurta, A.; Bahlis, N. J.
52
53
54
55 Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in
56
57
58
59
60

1
2
3
4
5
6 Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously
7
8
9 Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with
10
11
12 Lenalidomide (LEN) Failed. *Blood* **2017**, 130, 1812.

13
14
15
16
17 14. Chamberlain, P. P.; Lopez-Girona, A.; Miller, K.; Carmel, G.; Pagarigan, B.; Chie-
18
19
20 Leon, B.; Rychak, E.; Corral, L. G.; Ren, Y. J.; Wang, M.; Riley, M.; Delker, S. L.; Ito, T.;
21
22
23 Ando, H.; Mori, T.; Hirano, Y.; Handa, H.; Hakoshima, T.; Daniel, T. O.; Cathers, B. E.
24
25
26
27 Structure of the Human Cereblon-DDB1-lenalidomide Complex Reveals Basis for
28
29
30 Responsiveness to Thalidomide Analogs. *Nat. Struct. Mol. Biol.* **2014**, 21, 803-809.

31
32
33
34
35
36
37
38
39
40 15. Teo, S. K.; Chen, Y.; Muller, G.; Chen, R.; D. Thomas, S.; Stirling, D.; Chandula, R.
41
42
43 Chiral Inversion of the Second Generation IMiD CC-4047 (ACTIMID) in Human Plasma
44
45
46
47 and Phosphate-buffered Saline. *Chirality* **2003**, 15, 348–351.

- 1
2
3
4
5
6 16. Eriksson, T.; Björkman, S.; Roth, B.; Fyge, A.; Höglund, P. Stereospecific
7
8
9 Determination, Chiral Inversion In Vitro and Pharmacokinetics in Humans of the
10
11
12 Enantiomers of Thalidomide. *Chirality* **2003**, *7*, 44–52.
13
14
15
16
17 17. Mori, T.; Ito, T.; Liu, S.; Ando, H.; Sakamoto, S.; Yamaguchi, Y.; Tokunaga, E.;
18
19
20 Shibata, N.; Handa, H.; Hakoshima, T. Structural Basis of Thalidomide Enantiomer
21
22
23 Binding to Cereblon. *Sci Rep.* **2018**, *8*, 1294-1308.
24
25
26
27
28 18. Li, Z. S.; Schmauss, C.; Cuenca, A.; Ratcliffe, E.; Gershon, M. D. Physiological
29
30
31 Modulation of Intestinal Motility by Enteric Dopaminergic Neurons and the D2 Receptor:
32
33
34 Analysis of Dopamine Receptor Expression, Location, Development, and Function in
35
36
37 Wild-Type and Knock-Out Mice. *J. Neuroscience* **2006**, *26*, 2798–2807.
38
39
40
41
42 19. Deshaies, R. J. Protein Degradation: Prime Time for PROTACs. *Nat. Chem. Biol.*
43
44
45
46 **2015**, *11*, 634–635.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 20. Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.;
7
8
9 Bradner, J. E. Drug Development. Phthalimide Conjugation as a Strategy for In Vivo
10
11
12 Target Protein Degradation. *Science* **2015**, *348*, 1376–1381.
13
14
15

16
17 21. Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J. D.;
18
19
20 Crew, A. P.; Coleman, K.; Crews, C. M. Hijacking the E3 Ubiquitin Ligase Cereblon to
21
22
23 Efficiently Target BRD4. *Chem. Biol.* **2015**, *22*, 755–763.
24
25
26

27
28 22. Matyskiela, M.; Lu, G.; Ito, T.; Pagarigan, B.; Lu, C. C.; Miller, K.; Fang, W.; Wang,
29
30
31 N. Y.; Nguyen, D.; Houston, J.; Carmel, G.; Tran, T.; Riley, M.; Nosaka, L.; Lander, G. C.;
32
33
34 Gaidarova, S.; Xu, S.; Ruchelman, A. L.; Handa, H.; Carmichael, J.; Daniel, T. O.;
35
36
37
38 Cathers, B. E. Lopez-Girona, A.; Chamberlain, P. P. A Novel Cereblon Modulator Recruits
39
40
41
42 GSPT1 to the CRL4CRBN Ubiquitin Ligase. *Nature* **2016**, *535*, 252-257.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60